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CHAPTER 1: BACKGROUND AND SIGNIFICANCE
Epidemiology and Etiology of Basal Cell carcinoma:
Skin Cancer is the most common cancer in humans. Cancer statistics reveal
that incidence of skin cancer increases annually, making this cancer a growing
public concern [1]. The two main types of skin cancer are Melanoma, which is the
most aggressive and lethal form and accounts for about 4% of skin cancers, and
Non melanoma skin cancer (NMSC). NMSC consists of many subtypes. The two
major subtypes are squamous cell carcinoma SCC (16%) and Basal cell carcinoma
BCC (80%)[2]. BCC is rarely fatal and metastatic, less than 0.5% of BCC were
reported to metastasize in distal locations. However, the economic burden of BCC is
one of the highest due to its high prevalence with more than one million case
reported in the US. In spite of the relatively low mortality and metastasis rate, the
disease has been considered to be a public health issue due to its high frequency
and recurrence which increases morbidity caused by this disease [1, 3].
NMSCs are predominantly diseases of the Caucasian population as they are
especially prevalent in this ethnic group, mainly in areas of higher sun exposure[1].
Despite its relatively low incidence in Black, Hispanic and Asian groups, BCC is still
the most common skin cancer in these populations. Besides, there are differences
between Caucasian and non-Caucasian populations in the anatomical location of
the tumors, in their recognized etiologic factors and in prognosis [4].
Despite the increasing incidence of the disease in the younger population,
BCC is considered to be the disease of the elderly as the majority of patients
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diagnosed with this type of cancer are over 65 years of age. [1]. Skin cancer is
predominantly found in light-skinned Caucasians especially Type1and type 2 skin,
according to Fitzpatrick photo-typing [5]. Men were found to have higher incidence
and death rate of BCC comparing to women [1]. In general, the low socioeconomic
groups have less incidence of skin cancer than the higher socioeconomic groups,
but with lower survival rates and poor outcome [6], probably related to late diagnosis
due to lower accessibility of health care. Also, it was shown that incidence of BCC is
related to lack of UV protection during sun exposure, which may not be a priority for
lower socioeconomic population due to lack of awareness or financial resources.
Interestingly, an increase in prevalence of BCC among girls is emerging, especially
among high socioeconomic group. This increase is linked to frequent intentional
tanning. This procedure requires high exposure to UV light, which was recognized
as a major risk factor for BCC [7].
ALL types of NMSC, including BCC and SCC, are more common in immunecompromised patients. This includes patients who are taking immune suppressant
drugs such as organ transplant patients, and is unfortunately associated with a more
aggressive growth, higher risk of metastases, and poor outcome expectancy [2].
Despite high recurrence rate in BCC, multiple primary BCC lesions can be caused
by genetic syndromes. For instance, Gorlin-Goltz syndrome is usually characterized
by multiple basal cell carcinoma and keratocystic tumors along with other skeletal
abnormalities [8].
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Pathology and Pathophysiology of Basal Cell Carcinoma:
The vast majority of sporadic basal cell carcinoma lesions appear in areas of
the body that are frequently exposed to sun. The risk of developing BCC is not only
directly associated with UV exposure during adulthood, but it is also linked to
appearance of freckles and frequent incidence of sunburns during childhood[5].
In literature, BCC has been associated with some genetic factors. For
instance, the majority of BCC cases are associated with mutations in hedge-hog
pathway. Some of these mutations were reported to be in sonic hedgehog gene,
others were found in PTCH or SMO receptors [9]. Other genetic mutations that were
typically found in BCC are in P53 tumor suppressor gene, Ras oncogene, and
RUNX3 transcription factor encoding gene [5, 10]. Syndromes that include BCC
were related to genetic polymorphisms, especially when multiple tumors form
simultaneously in different areas including the trunk that is not highly exposed to
sun. Some of these polymorphisms that were associated with BCC were found in
glutathione S-transferase, NADPH and cytochrome P-450. In other cases, trisomy of
chromosome 6 was associated with genetic predisposition to BCC and was
associated with more aggressive tumor growth[5].
Early stages of BCC tumor appear like a small flat or raised sore of the skin
that never heals and grows slowly. It can look translucent or pearly, usually
surrounded by superficial vessels, and can bleed easily[5]. In medical literature
there are six subtypes of BCC that are well defined and classified. Subtypes of BCC
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include

nodular,

superficial,

pigmented,

morpheaform,

cystic

and

fibroepithelioma[11]. These subtypes differ in their appearance and aggressiveness.
The superficial and the nodular are considered to be less aggressive subtypes,
while higher aggressiveness is usually associated with the infiltrative, the
micronodular and the morphoeic subtypes of BCCs.
Histologically, BCC tissue appears to have a hyper-chromatic nucleus
surrounded by little cytoplasm with no variation in size and staining density. The
intercellular bridges are not well defined and they can be hardly recognized by
regular microscopes. BCC mass is lined by a fibromyxoid stroma with a lot of
collagen fibers and air bubbles [11]. The prognosis of basal cell carcinoma is
dependent on early detection and availability of treatments. However, survival rate is
100% in patients with un-metastasizing BCC. Once it metastasizes the prognosis
becomes very poor.
The risk of metastasis in BCC is related to the size of the tumor. Among BCC
tumors that are at least 3 cm in diameter, only 2% metastasize. while 50% of BCC
tumors that are greater than 10 cm form metastasis [5]. However, when BCC tumor
does not metastasize, it practices local invasion to surrounding tissue. When not
diagnosed at early stages, BCC can cause severe deformity which may leads to
morbidity or impact the patient’s quality of life after the treatment [5].
Vitamin D and its metabolism:
Vitamin D is a fat soluble vitamin. It is the only vitamin that can be obtained from
diet or can be biosynthesized in skin keratinocytes from precursors in response to
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sun exposure. The term refers to a group of antirachitic steroid derivatives with
similar biochemical activity. It is present in the diet from animal or plant sources as
vitamin D2 (ergocalciferol). Additionally, it is synthesized in the skin as vitamin D3
(cholecalciferol) from 7-dehydrocholesterol, which is present in abundance, by the
action of 290-320 nm UVB radiation.
Vitamin D3 is regulated in the body through different steps of activation and
inactivation that maintain adequate levels of the active form in blood and. In the first
step of activation, Vitamin D3 precursors, Cholecalciferol is hydroxylated in the liver
to form hydroxycholecalciferol or 25 hydroxyvitamin D3 [12, 13], or calcidiol. This
step is carried out by VD3 25-hydroxylase (CYP27A1) enzyme which catalyzes the
reaction of binding a hydroxyl group to vitamin D precursor at carbon number 25
producing 25(OH) VD3. This form of vitamin D is the major form of vitamin D in
blood stream and majority of vitamin D reservoir in the body is in that form. Even
though this form of vitamin D has some activity at the bone and intestine level, it
accounts for only 1% of the potency of the final biologically active hormone [12]. The
hormonal form of vitamin D is 1, 25-dihydroxycholecalciferol, or calcitriol, which is
formed after further hydroxylation in the kidney by the renal enzyme 25 OH VD31αhydroxylase (CYP27B1) [12, 13].
Interestingly, In addition to liver and kidney, keratinocytes express VD3 25
hydroxylase and 25 OH VD3 1α-hydroxylase. This indicates the presence of both
vitamin D biosynthesis and activation pathways in skin, showing the skin’s ability to
supply its own 1,25 hydroxyvitamin D when exposed to UV light [14]. Hence, skin is
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of unique importance in the synthesis, storage, and release of vitamin D into the
circulation [11]. Exposure to sunlight a few times a week can reduce the risk of
osteoporosis, osteomalacia, muscle weakness and fractures [15].
The hormonal active form of vitamin D, 1,25 (OH)2 vitamin D (calcitriol), is a
potent seco-steroid that acts by binding to an intranuclear receptor, the vitamin D
receptor (VDR) present in target tissues of most cells and tissues in the body [1618]. The abundance of the active form of vitamin D is regulated not only by
activation of cacidiol, but also by inactivation by calcitriol. This inactivation is
mediated by another renal enzyme called 25-Hydroxyvitamin D-24 hydroxylase
(24OHase), and it is also a cytochrome P450 enzyme (CYP24A1). Besides the renal
tissue, this enzyme was found to be produced in keratinocyte. 24OHase can
regulate vitamin D activity by initiating inactivation pathways for both calcidiol and
calcitriol. This enzyme can be induced by high levels of the active form of vitamin D
(1,25(OH)2D3), so it protects the body from excessive production of the hormonal
form of vitamin D[19].
Vitamin D and cancer:
There is a theory of that the severity of cancer could be reduced by oral
supplementation of vitamin D [20]. Vitamin D may play a role in the development
and progression of a wide spectrum of cancers [21, 22]. Prostate cancer [19,16],
non-small cell lung cancer [18], colorectal cancer [23, 24], breast and ovarian cancer
[20], [25, 26] are some of the cancers associated with vitamin D metabolism.
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Nevertheless, although skin cancer is the most common cancer in humans,
the relationship between skin cancer and vitamin D is not clear [4]. Exposure to
solar radiation is the main risk factor for the development of NMSC. Ultraviolet
radiation B (UVB) acts as the carcinogenic agent inducing DNA damage [3].
On the other hand, Vitamin D biosynthesis in the skin and the DNA damage
are both induced by the same spectrum of UVB radiation [3]. Vitamin D was found to
possess anti-proliferating and pro-differentiating effect [27]. A beneficial role of
vitamin D in cancer prevention has been reported. This fact led to the theory that
vitamin D biosynthesis in keratinocytes upon UVB exposure is potentially a defense
mechanism against cancer [2, 3].
However, Epidemiological studies failed to provide strong consistent
evidence for the anticipated benefit of vitamin D supplementation. Some studies
suggested a protective effect of vitamin D [28]. At the same time, other studies
concluded a positive correlation between pre-diagnostic serum levels of vitamin D
and the incidence of BCC [3]. For instance, a cohort study was conducted by Henry
ford hospital epidemiology group. Participants were 3223 NMSC patients who were
diagnosed between 1997 and 2009. Results suggested a positive correlation
between serum levels of Vitamin D and developing NMSC, and the observed
association was stronger with BCC than with SCC [29]. Many other studies reported
no association between vitamin D intake and the development of skin cancer
including the Nurses’ Health Study [27]. Besides, a prospective case-control study
assessing the relation between pre-diagnostic serum levels of 1,25-(OH)2 D3 and
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subsequent development of malignant melanoma (MM), failed to show significant
differences between cases and controls [30]. Another case-control study
investigated the relation between MM and dietary factors. Results showed no
association between melanoma risk and total vitamin D intake, calorie-adjusted
vitamin D intake, consumption of milk or vitamin D supplementation [31].
Furthermore, a cohort study investigated the association between BCC and diet
including dietary fat and vitamins (A, C, D and E), and showed no association
between these nutrients intake and BCC [32].
Several Laboratories investigated the effects of calcitriol (1, 25 (OH) 2 D3) in
cellular physiology. Calcitriol was shown to be involved in multiple cellular
mechanisms that include calcitriol or was shown to be involved in multiple cellular
mechanisms that include cellular growth, differentiation [33, 34], malignant cellular
invasion, apoptosis [16, 35], including UV induced apoptosis [34] and immune
modulation. In fact, calcitriol is one of the most potent regulators of cellular growth in
both normal and cancer cells [17]. The local production of calcitriol is postulated to
be important for regulating cell growth and therefore possibly preventing the cell
from becoming autonomous and developing into a unregulated cancer cell [17].
Additionally, in vitro studies have shown increased expression of vitamin D
receptor (VDR) in BCC [36], SCC [16] and MM [35] as well as increased expression
of mRNA of the main metabolites and enzymes involved in calcitriol metabolism in
BCC [36, 37] and SCC [16, 37]. However, the function of the VDR in SCCs is
unknown [16]. Furthermore, combination of 1,25 hydroxyvitamin D and retinoids has
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been reported to be effective in the treatment and prevention of cancerous and
precancerous skin lesions, such as actinic keratosis, SCCs, cutaneous T-cell
lymphomas and BCCs [16]. Studies done on Vitamin D receptor (VDR) null mouse
models show increased SCC’s when exposed to UVB, portraying a protective role
of VDR [38]. Additional studies show that Vitamin D and VDR are protective against
UVB induced skin cancer by altering signaling pathways and promoting DNA
damage response [38].
A large number of analogues of 1,25 hydroxyvitamin D with potent antiproliferative and pro-differentiating effects on cancer cells in vitro have been
developed and tested in animal models and a small number of human studies.
Calcipotriol, an analogue has been evaluated for topical treatment of advanced
breast cancer. A phase I clinical trial in patients with advanced breast and colon
cancer has been completed in the United Kingdom without evidence of clear
antitumor effects. Phase I/II clinical trials are currently underway in patients with
breast, pancreatic, hepatocellular carcinoma and myelodisplasia [13]. Therefore, the
exact role played by Vitamin D in skin cancer is still inconclusive which calls for
more direct approach to determine the biological role of Vitamin D in the
development of several types of cancers including colon cancer and skin cancer
[39, 40] .
The Institute of Medicine recommended that the daily allowance for vitamin D
should be 15 μg (600 IU). However, the RDA for seniors above 70 years old was
increased to 20 μg (800 IU), with the safe upper limit set at 100 μg (4,000 IU) for all
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adults [41]. However, it has been largely accepted in clinical practice that
administrating large doses of vitamin D to skin cancer patients is recommended as
part of any treatment and/or prevention regimen
Vitamin D and mTOR pathway:
The mammalian target of rapamycin (mTOR) is an important cell signaling
protein and it plays a role in many important cellular functions. mTOR impact the
regulation of cell growth, cell cycle, nutrient status, as well as many transcription and
translation factors in the cell [42]. mTOR is considered serine/threonine protein
kinase that belongs to the (PIKK) family. This protein is large and consists of
multiple domains that forms two distinct complexes called TORC1 and TORC2.
mTOR is highly conserved among many species, that we can find similarity in the
structures and the functions between mTOR in humans, rats, mice and TOR in
plants, drosophila and even fungi [43, 44]. The tow TOR complexes are composed
of different domains and hence possess different functions and roles. For instance,
Only TORC1 can bind to Rapamycin but not TORC2.
mTOR regulates different cellular functions through interacting with different
pathways. For example, it impacts translation of some proteins related to cellular
growth in response to amino acids, especially the branched amino acids, through
interaction with PI 3K signaling. On the other hand, mTOR regulates the translation
of other proteins through the phosphorylation of pS6K and 4E-BP1, which result in
activation of the first one and inhibition of the later [44].
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Many mechanistic studies suggested that Vitamin D can exert differentiation
and inhibits proliferation of cancer cells by blocking mTOR through increasing
REDD1, which is mTOR inhibitor [45-47].
mTORC1 is part of a vital regulatory pathway in the cell which is Ras-PI3KAKT-mTOR pathway. mTOR responses are initiated by PI3K impacts mTOR
pathway through Akt which is serine/threonine kinase. AKT is activated by
Phosphorylation in two locations serine 473/threonine 308 which in turn
phosphorylates and inhibits the activity of TSC1/2 (tuberous sclerosis protein
complex). TSC complex inhibition results in suppression of Rheb protein (Ras
homolog enriched in brain), which increases the activity of mTOR complex [47].
mTOR itself is a protein kinase that influence cell cycle regulation, cellular growth,
metabolism, and autophagy by phosphorylation of two essential proteins. The first
one is 4E-binding protein (4E-BP) that is involved in initiation of ribosome
biogenesis. The second protein that gets phosphorylated by mTOR is ribosomal
protein S6 kinase (p70S6K) impacting protein synthesis [45, 47]. mTOR
phosphorylates TIF4E-binding protein (4EBP), impairing its ability to bind to TIF4E
protein. P-4EBP and p-S6K can be used as indicators of mTOR signaling [48] .
VDR is known to negatively regulate mTOR through up-regulating REDD1
(regulated in development and DNA damage response 1) protein. The gene
encoding REDD1 protein is VDR target gene that contains VDRE in its promoter
[45]. Up-regulation of this gene is known to block the activity of mTOR gene through
promoting the activation of TSC1/2 complexes, which in turn inhibits Rheb resulting
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in suppression of mTOR activity [47] . VDR effect on its target gene transcription
regulation was shown to be impaired when some proteins called VDREBP (vitamin
D response elements binding proteins) are up-regulated as they compete with VDR
over the binding sites of its response elements in the promoter of the target gene
Protein analysis shows that REDD1 is successfully up-regulated in cancer tissue
despite the elevation in VDREBP.
Active AKT is known to block the assembly and activation of TSC1/2 complex
which opposes with the effect of VDR. Up-regulation of PI3K-AKT-mTOR pathway
was shown in many other cancers such as breast cancer, and it was anticipated to
alter the cancer response to endocrine treatments [48, 49]. Upstream of this
pathway there is Ras gene which is an oncogene and was reported to have gain of
function mutations which result in up-regulating two main pathways, PI3K-AKTmTOR and Ras-Raf-MEK-ERK pathway [50]. Ras point mutations are common, and
were repeatedly reported in many types of cancers including, but not limited to,
colon, skin, and breast cancers [51].
Hh-Gli pathway and basal cell carcinoma:
PTCH receptor is a plasma membrane receptor that is integrated in the
phospholipids bi-layer of the membrane. The normal function of PTCH is to bind and
inhibit another plasma membrane receptor called smoothened (SMO). This binding,
and hence the blocking of SMO is released after PTCH receptor binds to its ligand
(Hedgehog) protein [46]. Over expression of this pathway may result from over
expression of the Hh ligand causing continuous suppression of PTCH receptor, or
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from truncation of the PTCH receptor resulting in failure to bind to SMO, and
sometimes from a gain of function mutation in SMO itself [52]. SMO, when unbound,
can activate a signal transduction pathway that result in over expression of
downstream glioblastoma Gli1 and Gli2 signaling proteins [52, 53], and switching the
Gli code to the transcription activation mode [54].
Gli code system involves three transcription factors Gli1, Gli2, and Gli3.
These three proteins cooperate to regulate cellular function in response to upstream
signals [54]. Gli1 is the main transcription activator, while Gli3 is a transcription
repressor. Gli2 can operate as either activator or repressor, depending on the level
of C-terminal cleavage [53]. Gli2 and Gli3 possess a transcription repression
function only in the cleaved form. Gli2 turns to a transcription activator when it is not
cleaved, and non-cleaved Gli3 is inactive [54]. Hedge-hog signaling pathway
controls the expression of Gli1 and the cleavage of Gli proteins, resulting in
switching the Gli-code between the transcription inhibition and the activation modes
[53]. In presence of Hh protein, SMO is active. Consequently, Gli1 is
transcriptionally expressed and the cleavage is inhibited, rendering Gli-code in the
transcription activation mode [9, 54]. On the other hand, when SMO is inhibited by
PTCH, Gli1 becomes transcriptionally inactive. Also, Gli2 and Gli3 will be expressed
and cleaved. In this case, Gli-code is in the transcription inhibition mode [53, 54]
Gli1 target genes are critical for cellular regulation and growth control. For
instance, up-regulation of Gli1 increases the expression of transforming growth
factor-β (TGF-β) and epidermal growth factor (EGF) [53, 55]. Over expression of
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Gli1 is common in many types of cancers as it facilitates the rapid growth of the
cancer [54]. Up-regulation of un-cleaved Gli2 results in over expression of the antiapoptotic protein bcl-2[52]. Elevated levels of bcl-2 can block the intrinsic apoptosis
pathway [35].
Hedge-hog pathway mutations characterize basal cell carcinoma, resulting in
excessive signaling of the pathway [46]. Over-expression of Hh-Gli pathway results
in modifying the Gli-code, and affects tumor progression and recurrence [53, 56].
Some studies discussed vitamin D ability to inhibit Hh-Gli pathway signaling and
promote differentiation [46], and facilitate alterations in the Gli-code [46, 53].
Interestingly, down-regulation of Hh-Gli signaling by vitamin D is independent from
its nuclear receptor VDR [57]. In fact, PTCH utilizes the active form of vitamin D and
its derivatives for SMO inhibition [58]. What is more, vitamin D supplementation to a
hedgehog mutant mouse was shown to reduce Hh-Gli signaling [56]. These results
support the expected benefit from supplementing BCC patients with high doses of
vitamin D.
Hypothesis and Specific Aims:
Cancer in general is an increasing problem. Basal cell carcinoma has the
highest incidence and recurrence, and thus the greatest economic burden [1, 3].
Many factors were shown to impact the risk for developing BCC such as age,
gender, ethnicity, socioeconomic status, and sun exposure [1]. Vitamin D can be
obtained from diet or biosynthesized in keratinocytes. Vitamin D3 synthesis from its
precursor (7-dehydrocholesterol) is initiated by exposure to UVB radiation of wave
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length between 290-320 nm [3]. The correlation between this exact range of
radiation with onset of skin cancer raised many controversies related to the benefit
of sun exposure [3, 7] .
Vitamin D is known to have an anti-proliferative and pro-differentiating effect
through impacting some signaling pathways in the cell [28, 29]. Vitamin D3 activates
its nuclear receptor VDR which hetero-dimerize with RXR and operates as a
transcription factor[59]. Upon binding to a specific response element in the gene’s
promoter and recruiting the required co-activators, VDR initiates the transcription of
the target gene [60].
It was shown that Up-regulation of VDR target gene REDD1 results in
negative regulation of mTOR via activating TSC1/2 complexes [45]. Down-regulation
of mTOR pathway signaling results in reduced 4EBP and S6K phosphorylation,
which consequently reduces cellular growth and proliferation [45, 47].
Vitamin D was also shown to have anti-proliferation activity by downregulating hedgehog-Gli pathway signaling in a VDR independent fashion [57].
Binding of Hh protein ligand to PTCH receptor blocks its ability to inhibit SMO
receptor. Continuous activity of SMO leads to up-regulating Gli1 and shifting the Gli
code to the transcription activation mode [53]. Research illustrated that PTCH
inhibits SMO through vitamin D3 and its derivatives [58]. Supplementing a hedgehog
mutant mouse model with vitamin D was shown to reduce Hh-Gli signaling [56].
Hedgehog mutation is very common in basal cell carcinoma [47, 56].
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Due to the anticipated benefit of vitamin D, current recommendations include
high dosage supplementation of vitamin D as a part of skin cancer treatment
regimen[41]. However, the correlation between vitamin D and BCC is not clear due
to the shortage of mechanistic studies and the inconsistency of the data obtained
from the epidemiological studies [3, 27]. Interestingly, many epidemiological studies
question effectiveness of Vitamin D supplementations on BCC treatment including a
study performed in southeast Michigan[29]. Besides, many practitioners have
continuously observed ineffectiveness of the Vitamin D supplementation on BCC
treatment (personal communication).
On the other hand, Vitamin D is known to be an immune suppressant [61, 62]
. It was reported that compromising the immune function is associated with
increasing incidence of NMSC. Organ transplant patients who are taking immune
suppressant medications have significantly higher risk of developing NMSC [1].
The purpose of this study is to investigate the sensitivity of BCC tissue to the
anti-proliferative effect of Vitamin D at the molecular level. Hence, predicting
possible advantages/disadvantages of vitamin D supplementation for BCC patients.
Based on our preliminary data, practitioner’s observations, and epidemiological
studies we hypothesize that the anti-proliferative impact of vitamin D is
compromised in BCC thus rendering Vitamin D supplementation ineffective and
potentially detrimental. To test our hypothesis, we will investigate the following aims:
1.

Specific Aim1: To determine Vitamin D metabolism pathway including

Vitamin D activation genes, Vitamin D receptor (VDR), and VRD co-activator in all
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specimens from BCC patients (cancer, proximal, Distal tissues) as compared to the
controls specimens.
2.

Specific Aim2: To determine genes and pathways up/down stream of

VDR that impact proliferation and/or differentiation in all specimens from BCC
patients (cancer, proximal, distal tissues) as compared to the controls specimens.
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Figure 1.1: Vitamin D structure and activation: a) vitamin D3 is formed from
7-hydroxycholesteril in keratynocytes or obtained from diet. b) calcidiol is the major
form of vitamin D in blood stream. It is formed from vitamin D3 by hydroxylation,
mediated by the hepatic enzyme (VD3 25-hydroxylase). c) calcitriol is the active
hormonal form of vitamin D. it is formed from calcidiol by a second hydroxylation
reaction mediated by the renal enzyme (25(OH) VD3 1α-hydroxylase). d) Vitamin D
is inactivated by further hydroxylation the renal enzyme (1α,25(OH)2 VD3 24hydroxylase).
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Figure 1.2: mTOR pathway: The Mammalian Target of Rapamycin protein
kinase responds to environmental factors, which impact its activity in various ways.
Manipulation of TOR activity can be initiated through AKT, AMPK, TSC, or inhibition
through direct binding to mTOR complexes such as rapamycin. mTOR impacts
important cellular functions and growth through S6K and 4EBP phosphorylation
which control the translation process.
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CHAPTER 2: RESEARCH DESIGN AND METHODS
This case control study is a human study with mechanistic approach. Our
samples are tissue specimens excised from cases and controls in Henry Ford
Hospital. Subjects were recruited by dermatology research group after obtaining the
required protocols approved by Henry ford health system IRB (institutional review
board).
Participant Selection:
Participants are either basal cell carcinoma patients (Cases), or non-cancer
patients (Controls). Subject’s eligibility for the study was determined according to the
inclusion and exclusion criteria in the protocol. Approval of the protocol was
obtained prior to starting the recruitment process.
BCC Patient Selection (Cases):
Basal cell carcinoma participants are 20 patients from south east Michigan
from both genders. Subjects’ age ranges between 46 and 89 years with average 74
years old. All patients were diagnosed with BCC in the head and nick area. In
details, locations include nose, ear, cheeks, eye canthus, lips, chin, neck, temple,
and forehead.
Inclusion Criteria: For inclusion, the subject must:
1. Be at least 18 years old at time of participation.
2. Have a basal-cell carcinoma and accept to have it excised.
3. Agree to abide by the investigator’s guidelines regarding skin cancer screening;
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4. Be able to understand the requirements of the study and the risks involved, and to
sign the informed consent form.
5. Agree to follow and undergo all study-related procedures (blood sample).
Exclusion Criteria: Subjects will be excluded if any of the following apply:
1. Women who are lactating, pregnant, or planning to become pregnant.
2. Patients with a recent history of serious systemic disease.
3. Patients with history of intestinal malabsorption, resection, or bypass, which are
known to affect vitamin D nutrition.
4. Patients receiving pharmacologic vitamin D replacement (i.e., 50,000 IU/ week or
more), as well as systemic or topical agents involving vitamin analogs or derivatives
(such as Dovonex) in the last 4 months.
5. Patients undergoing PUVA (Psoralen Ultraviolet A) therapy.
6. Patients using medications known to affect vitamin D metabolism such as
Dilantin, Phenobarbital, and Cholestyramine.
7. Patients on immunosuppressive therapy.
8. Any reason the investigator feels the patient should not participate in the study.
Control selection:
Control subjects are six healthy individuals whose age is higher than 50 old.
Cases and controls are coming from the same population and geographic area of
south east Michigan. Controls were never diagnosed with skin cancer. All controls
were scheduled for eye-lifting procedure, and agreed to donate their excised facial
tissue for this study. This assured comparable location of the skin specimens, and
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therefore the accessibility of sun light among specimens. All inclusion, exclusion,
legal documentation, and recruiting procedures were similar for cases and controls
with the exception of BCC diagnosis. While it is an inclusion criterion for the cases;
cancer diagnosis is considered an exclusion criterion for the controls.
Recruitment Process:
Patients with non-melanoma skin cancer coming to Henry Ford Hospital for
treatment were the candidates for this study. Medical records of eligible candidates
were reviewed first to determine if any exclusion criteria applied. Candidates that
were still eligible after record review were contacted by an investigator, coinvestigator, or collaborative member. Invitations to participate were delivered to
candidates via mail or phone. Eligible subjects who showed interest in participating
in this study were scheduled for a screening visit.
Screening visit:
The study involved attending Henry Ford outpatient facility for one screening
visit prior to the actual tumor excision and blood draw appointment. Failure to attend
the screening visit resulted in exclusion of the subject from study. Many critical
procedures were performed during this visit. First, authorized members of the study
team confirmed inclusion and exclusion criteria from the medical record and the
interview. Also, participant’s skin was examined, typed, and assessed for skin
cancer risk. Finally, the interviewer provided educational consent to the subject
about the study, and obtained the required legal permissions.
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1.

Inclusion/Exclusion Criteria determination, Informed Consent and

HIPAA Authorization: Patients were assessed for inclusion and exclusion criteria. If
the patient was found eligible to participate in the study, written informed consent
and written authorization to disclose protected health information under HIPAA
regulations were obtained from the patient. This was completed prior to performing
any procedure related to the study by study staff as listed in the IRB application.
Sufficient time was given to answer subjects’ questions, and patients were not
forced to participate by any means.
2.

Demographic Information: Demographic data that were collected at

the screening visit, including gender, age and skin photo-type. All our participants,
cases and controls, were Caucasian. BCC patients were 6 males and 14 females.
Descriptive statistics was performed on age data for cases from both genders. Age
of patients at time of diagnosis was tested for normal distribution.
3.

Pertinent Medical History and risk factors: At the visit, information

related to the current or past medical history of skin cancer was obtained. This
included date of onset, anatomical areas affected, disease course, and result of
previous biopsies, previous treatments, and treatment responses. Presence of risk
factors for skin cancer (such as previous history, family history, degree of exposure
to UV radiation, history of several previous severe sunburns especially in childhood
and adolescence) was documented. Other relevant information consisting of, but not
limited to, complete past medical history, including the presence of systemic
disorders and conditions causing an immune-compromised state would be
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acknowledged. Also, Interviewer obtained a list of all systemic and topical
medications taken by the subject at the time recruitment.
4.

Dermatological Examination: A focused dermatologic examination was

performed for all patients. It included skin photo-typing and skin cancer screening for
suspicious lesions. All participating cases were diagnosed with basal cell carcinoma
lesion in the neck and head area. Exact distribution of cancer locations is shown in
table (2.1).
Excision of tissue specimens from BCC patients:
Dermato-surgeons at Henry Ford Hospital excised tissue specimens from
the enrolled patients. Specimens were collected from each recruited BCC patient
from three different locations; the cancer mass itself, normal tissue surrounding the
cancer and directly adjacent to it (proximal), and normal tissue relatively far from the
cancer location (distal). Distal location is at least one inch far from the proximal
(figure 2.2). Proximal tissue was separated from the cancer mass under the
microscope by a specialized pathologist to avoid contamination of proximal tissue
with cancer cells. Collected specimens will be snap-frozen in liquid nitrogen
containers. Tissue specimens were then transported to our lab, and kept in liquid
nitrogen for further processing and analysis.
Experimental Procedures:
1.

Gene Expression Analysis:
a)

Tissue processing and total RNA extraction: Snap-frozen tissue

specimens were kept in liquid nitrogen until the time of processing. Tissue

27

specimens obtained from the same patient (Cancer, proximal and distal) were
handled and processed at the same time. A piece that weighs approximately 50 mg
from each tissue specimen (From BCC patients and controls) was used for RNA
extraction. Frozen tissue was homogenized with 1000 ml of the lysis buffer using the
polytron homogenizer. RNA was then isolated by RNeasy spin column in
accordance to the protocol provided with the RNeasy RNA kit (Qiagen, Valencia,
CA). Extracted RNA was stored at (-80 ℃).
b)

Nucleic

acid

concentration

assessment:

Nano-drop

spectrophotometer technology was used to measure the concentration of RNA and
cDNA in our experiment. The sample’s absorbance was measurements in sample
volumes of 1μL, and analyzed by a computer linked to the instrument. The Nucleic
acid concentration will be calculated by the software.
c)

RNA Gel Electrophoresis: Quality of the isolated RNA was assessed

using the denaturing agarose gel electrophoresis. 1.5% agarose gel was prepared
with 10X mops buffer (10 ml) and distilled water (72ml), and then mixed with 18ml of
formaldehyde and solidified in a gel casket. 25μL of sample buffer and 1μL of
ethidium bromide were added to 5μL of RNA sample before being loaded on the gel.
Electrophoresis was run at 150 volt at room temperature for 1 hour. The formed
bands were visualized under UV light in the Trans-illuminator. This method enables
both quantitative and qualitative detection of the RNA, as the fluorescence density in
the bands indicates the quantity.
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d)

cDNA preparation: cDNA was prepared 1μg of RNA. The first strand

was synthesized by the random primers according to the protocol provided with
ImProm-II reverse transcriptase system from (Promega, Madison, Wl). cDNA was
then purified in a Qiaquick spin columns provided with the QIAquick PCR
Purification Kit in accordance to the provided protocol by the manufacturer (Qiagen,
Valencia, CA). Nano-drop spectrophotometer technology was also used to quantify
the concentration of the cDNA preparations before they were stored at -20 ͦ C.
e)

Quantitative Real-Time PCR: Gene expression profile in the cancer,

proximal, distal tissue from the BCC patients as well as from the controls was
analyzed using the quantitative real-time PCR assay. The real-time PCR reactions
were prepared according to the protocol provided with the LightCycler 480 SYBR
Green I Master kit from (Roche, Mannheim, Germany). The studied genes were
amplified in a hot-start reaction by performing a pre-incubation step at 95 C
̊ for 5 min
before 40 amplification cycles. Each cycle consisted of 10 seconds at 95 C
̊ followed
by 30 seconds at 60 ̊C with an end point measurement of cyber green fluorescence.
Dissociation curve was generated in the third step by heating the mixture to 95 ̊C
for10 seconds followed by cooling down to 60 C
̊ for 30 seconds and heating to 95 C
̊
again for 30 seconds with all points measurements of the dye fluorescence.
We analyzed the expression of 17 genes of interest in the collected tissue
samples. The expression of each gene was studied in all samples, obtained from
cancer patients (cancer tissue, normal proximal, and normal distal tissue) and from
controls, in the same 69 multiwall plate to be loaded in the thermo-cycler at the
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same time. A different set of primers was used in each run. Each set of primers was
specifically designed to amplify one of the studied genes. Our studied genes are:
VDR, 1αOHase, 25OHase, 24OHase, RPL13, PARP-1, src, DRIP, P53, Bcl-2,
Apex-1, VEGF, MDM2, Gli1, Ras, GADD45A, and Caspace-3. In this study, 3 μL of
template cDNA was added to each reaction of a total volume of 25 μL. Primers for
VDR, 1αOHase, 25OHase, 24OHase, SRC, DRIP were designed in our lab using
the (Beacon Designer, PREMIER Biosoft International) program. Gli1and Ras
primers sequences were taken from articles [51, 55] respectively. Sequences of
primers used to amplify these genes are shown in table (1). Primer sets that were
used to study other genes were purchased from (Real time Primers, LLC; Elkins
Park, PA). They were designed and synthesized by the selling company.
Protein Expression Analysis:
a)

Protein extraction: Whole cell protein extract was prepared from 100

mg of the skin tissue using RIPA buffer (Igepal CA-630, sodium deoxycholate, SDS
0.1%, and 1X PBS) with protease inhibitors added just before use (β-Mercaptoethanol 10mM, PMSF 10μg/ml, pepstatin A 1ug/ml, Triton X-100 15μl/ml, Protease
inhibitor 1X). Skin tissue was first crushed with the buffer manually using porcelain
mortar and pestle, and then was fully homogenized using the Teflon homogenizer.
Samples were left on ice before they were centrifuged for 10 minutes at 14000 rcf
and 4℃. Protein concentration in the supernatant was quantified by performing
Bradford assay using Protein Assay Kit I (Bio-Rad, Hercules, CA, USA). Whole cell
extracts were stored in -80 ͦC.
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b)

Western Blot Assay: Protein expression was analyzed by performing

western blot assay with 100 μg of the whole cell extract. Protein extract was run on
10% SDS-PAGE gel to perform the western blot assay. Protein bands were
transferred to a nitro-cellulose membrane, which was then blotted by incubation with
manufacturer-recommended dilutions of protein- specific primary antisera developed
against our target protein (s), followed by incubation in secondary anti-body. Bands
were then incubated in SuperSignal West Pico chemiluminescence substrate
(Pierce Biotechnology), and visualized and quantified using a Chemimager system
(AlphaInnotech, San Leandro, CA, USA). Protein quantity was measured as (IDV) of
the band per microgram of protein. The remaining gel after transfer was stained
using gel code blue (Pierce Biotechnology) to ensure equal loading and uniform
transfer.
The primary antisera used in this study were specifically against: VDR (D-6,
Santa Cruz Biotechnology, Santa Cruz, CA, USA), REDD1 (poly Ab, proteintech
group inc, Chicago, IL, USA), 4E-BP1 (T37/46, Cell Signaling Technology, Beverly,
MA, USA), VDREBP (hnRNP, Santa Cruz Biotechnology, Santa Cruz, CA, USA), PAKT (S473, Cell Signaling Technology, Beverly, MA, USA), P-AKT(T308, Cell
Signaling Technology, Beverly, MA, USA). The secondary anti-bodies that were
used are: Goat-Anti rabbit IgG-HRP linked (Santa Cruz Biotechnology, Santa Cruz,
CA, USA), and Goat-Anti mouse IgG-HRP linked (Santa Cruz Biotechnology, Santa
Cruz, CA, USA). Results are shown as integrated density value (IDV) per microgram
of protein.
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2.

Detection of KRas Mutation:
a)

ASB-PCR Assay: KRas mutation was detected in the tissue samples

from BCC patients (cancer, proximal, and distal) as well as from controls using the
ASB-PCR (Allele-Specific PCR with Blocker). The technique was applied as
described in literature [51]. Each mutant-specific forward primer was designed to
detect a specific mutant (ras) genotype. Amplification of the wild type sequence is
prohibited by adding a blocking agent, which is complementary to the wild type
sequence with a phosphorylated 3` end rendering it un-extendable ( Figure 2.1).
Mutant allele specific primers and the wild type blocker were designed as forward
primers. All mutant specific, wild type, and blocker primers were used with the same
reverse primer.
b)

Primers used in Detecting KRas point mutation in BCC tissue

specimens: Four different mutant specific primers were used. Each primer was
designed to detect a different single point mutation, and has the mutated base
located in the 3’ end of the primer sequence. The mutations that are detected in this
assay are on the Guanine bases in the locations 215 and 216 of the primer. The
mutant specific primer 2.1 contains the substitution of G in the location 216 with T.
Mutant specific primer 4.1 has G 215 substituted with A. Mutant specific primer 5.1
contains the substitution of G 215 with C. Finally, mutant specific primer 7.1 has G
216 substituted with C. The blocker is complementary of the wild type, and has the
wild type form of the mutated bases G 215 and G 216 located in the center of the
blocker sequence with a phosphorylated 3’ end. The sequences of the primers used

32

in the assay, and the associated mutations detected by each primer are shown in
Table 2.2. Melting temperatures are also distinct between the mutant specific
primers and the wild type specific blocker. Melting temperature of the blocker is
equivalent to the PCR extension temperature, while Tm of the mutant allele specific
primer is about 10 ℃ below that. The last difference between the two types of
primers is the concentration used in the reaction. To effectively block the
amplification of the wild type allele in the PCR reaction, the concentration of the
blocker should be four times that of the mutant specific primer in the reaction.
3.

Data Analysis and Testing For Statistical Significance:
Gene expression in all samples was measured as fold increase of the

controls average. Fold change values for samples from tissue different groups were
compared to each other. An array of three housekeeping genes (RPL13A, B.actin,
and GAPDH) was used as an internal control to normalize real-time PCR data.
B.actin protein level was used as an internal control for all western-blot protein
analysis assays. ANOVAs analysis was performed between the four specimen
groups (cancer, proximal, distal, control) to test for significant difference between the
means, followed by Bonferroni’s multiple comparison’s test between each two
groups. In all tests, a P value ≤0.05 was considered significant. Fold change values
were calculated from the real-time (Ct.) Values using the PCR array analysis
software. Real time data results are illustrated in two forms, column graph
representing only groups’ averages and SEMs, and scatter plots for individual data
points. Protein expression analysis is shown in a column graph with averages and
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SEMs. Individual samples in protein assays were shown in a picture of the westernblot membrane image. Groups with similar letters in the graphs are not significantly
different from each other. Pvalue≤0.05 is considered significant.
Age data for participating BCC patients, was tested for normal distribution
through Kolmogorov-Smirnov normality test using SPSS software. The number of
BCC patients in each age group was plotted against the center of its age range; a
trend-line was drawn using the Microsoft Excel program.
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Table 2.1: Distribution of BCC locations among participants: All of the 20
cases recruited in our study were diagnosed with basal cell carcinoma in the head
and nick area. On the other hand, Normal tissue from the control participants was
excised during eyelid-left surgery, assuring comparable sun exposure among
different tissue groups.
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Cancer Location

Number of Cases

Nose

4

Cheek

1

Eye canthus

1

Ear

3

Neck

2

Temple

4

Forehead

3

Chin

1

Lip

1

Total Cases

20
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Table 2.2: The Real-Time primers sequences: Real time gene specific
primers were used to detect the message of the target genes. Sequences of both
sense and antisense primers used in our study are shown in the table below.
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Gene

Sense Primer Sequence

Antisense Primer Sequence

VDR

5 -́ GTCGTCCATGGTGAAGGA-3 ́

5 -́ CCAGTTCGTGTGAATGATGG-3 ́

1αOH

5 -́ CCGGGAGAGCTCATACAG-3 ́

5 -́ TGTTTGCATTTGCTCAGA-3 ́

25OH

5 -́ AGCAAATAGCTTCCAAGG- 3 ́

5 -́ GGCAAGTACCCAGTACGG-3 ́

SRC

5 -́ TGAAAGTGGAAAAGAAAGAA

5 -́ GTCAAGGTCAGCTGTAAA

CAGATG-3 ́

DRIP

5 -́ GGAGCATCACAGTGGTAG
TCAGG-3 ́

Gli1

5′-CTCCCGAAGGACAGGTAT
GTAAC-3′

CTGGC-3 ́
5 -́ CCGCTTTGGAGGCTTATC
TTTGC-3 ́
5′‐CCCTACTCTTTAGGCACT
AGAGTTG-3′
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Table 2.3: Sequences of the primers used in detection of KRas gain of
function mutations: ASB-PCR technique was employed in the detection of point
mutation of KRas oncogene in BCC tissue samples. It involves the usage of Mutant
allele-specific primers (ASP) accompanied with wild-type allele specific Blocker. 6
different ASPs were used to detect 6 possible point mutations, with the mutated
base located at the 3` end of the primer. The wild-type blocker is a primer that
complements the wild-type sequence with the possibly mutated base located at the
center of the primer sequence. The blocker has a phosphorylated 3` end to block
the extension of the wild-type allele.
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WT
MUT 2.1

PRIMER SEQUENCE (FP)
AAACTTGTGGTAGTTGGAGCTGG
TGTGGTAGTTGGAGCTGA

Nucleotide
Substitution

G216A

MUT 4.1

AACTTGTGGTAGTTGGAGCTA

G215A

MUT 5.1

ACTTGTGGTAGTTGGAGCTT

G215T

MUT 7.1
BLOCKER
REVERSE PRIMER

TGTGGTAGTTGGAGCTGC
TTGGAGCTGGTGGCGTAGG-PO4
TGATTCTGAATTAGCTGTATCGTCAA

G216C
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Figure 2.1: Illustration of tissue excision protocol: three tissue specimens
were excised from each recruited basal cell carcinoma patient. The first specimen is
the BCC mass itself and is named (Cancer). The second tissue specimen is the
normal tissue adjacent to the BCC mass and directly surrounding it. This piece of
tissue was carefully separated from the cancer mass under the microscope by a
specialized trained pathologist to insure uniformity of the cell type and avoid
contamination of the tissue specimen with cancer cells. This specimen is named
(Proximal) to distinguish it from the other normal tissue specimen obtained from the
same patient. The third specimen is a normal tissue excised from a location that is
relatively far from the cancer mass, and was named (Distal).
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Figure 2.3: Illustration of ASB-PCR technique that was used to detect KRas
point mutation in BCC tissue specimens: Shown example represents KRas mut 5.1
point mutation, the mutation that was successfully detected in our BCC patients. The
mutation involves the conversion of G215 to T. a) The (mut 5.1) mutant allele
specific primer is anchored at the 3` end with the T base that base pairs with the A.
When the primer is annealed to the mutated sequence in the cDNA, perfect
matching causes the amplification of the mutant allele. b) The wild-type specific
blocker is a primer that is complementary to the wild-type allele sequence.
Therefore, it perfectly base pairs with wild-type allele in the cDNA sample. The 3`
end of the blocker is phosphorylated rendering the wild-type allele unamplified. C)
shows the similarity between the wild-type allele primer and the wild-type allele
blocker.
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G215→T
a) Mutant allele-specific
Primer (Mut 5.1)
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No Amplification

C

G215
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G
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CHAPTER 3: RESULTS AND ANALYSIS
This case-control study aims to explore Vitamin D metabolism in basal cell
carcinoma tissue and in normal tissue from both BCC patients and controls. Hence,
predicting the sensitivity of different tissue groups to the anti-proliferative effect of
vitamin D. We collected three tissue specimens from each BCC patient; cancer
tissue, normal tissue proximal to the cancer, and normal tissue distal to the cancer.
Eyelid tissue from cancer-free subjects was used as a control.
Analysis of cases and controls demography:
Cases and controls were recruited in Henry Ford Hospital after the approval
of our protocol. Twenty BCC patients were recruited in this study. Out of which, 14
were males and 6 were females. Patients’ ages ranged between 46 and 89 years.
All patients were diagnosed with BCC in the head and neck area. Controls were 6
cancer-free individuals whose age was greater than 50 years at the time of
participation. Cases and controls were from south east Michigan. Controls were prescheduled for eyelid lifting procedure, and have agreed to donate their excised
tissue for this study. Obtaining all specimens from sun-exposed locations reduces
the chance that observed differences among tissue groups are related to variations
in sun exposure. All participants, cases and controls, were Caucasian individuals,
which eliminated race-related differences. However, all controls were females as no
male participants could be successfully recruited.
Analysis of age distribution among BCC patients: Cases ages at the time of
diagnoses ranged between (43-89 years old). Their average age was 74 years, and
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both the mode and the median age were 80 years old. BCC cases age data failed to
pass the KS normality test indicating that they were not normally distributed around
the mean age, at least in our sample (Table 3.1).
To illustrate the abnormal distribution of patients’ age, they were grouped
based on their ages at time of diagnosis. These groups were ≤45, 46-55, 56-65, 6675, 76-85, and 86-90 years old. The number of patients within each age group was
plotted at the middle age range covered in that group (figure 3.1). The trend line
indicated that the number of cases diagnosed at each age was increasing gradually
as the age increase until 75 years of age. A peak in the number of cases was
formed between 75 and 85 years, followed by a rapid decline after 85 years of age.
The trend line appears skewed, which is compatible with the result of the normality
test.
Total-RNA yield from BCC patients’ tissue specimens:
Specimens obtained from the same person (cancer, proximal, distal) were
handled at the same time throughout the process of RNA extraction and purification.
Cancer tissue showed tendency to yield more RNA concentration than the normal
tissue from same person. Figure (3.2) shows an image of denaturing RNA gel
electrophoresis for RNA extracts. The three specimens were taken from the same
person, at the same time, and had the same weight before processing. In
agreement with the picture, RNA nano-drop spectrophotometer quantification
revealed that cancer tissue yielded about 2-2.5 times as much RNA as the normal
tissue of the same patient.
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In order to neutralize this factor and avoid any impact on the accuracy of our
results, gene expression analysis was normalized to total-RNA quantity. RNA
extract volumes used for cDNA preparation were adjusted to contain equal amounts
of RNA (1μg of RNA). Furthermore, cDNA concentrations were quantified once
more before they were used for gene expression analysis. Finally three
housekeeping genes (RPL13, GAPDH, and β-actin) were used as internal controls
to normalize the data using the PCR array analysis program.
Analysis of the expression of vitamin D metabolism key genes:
Studying the differences in vitamin D metabolism key genes among tissue
groups is a main objective of this study. We analyzed the expression of the key
genes in metabolizing vitamin D 25OHase, 1αOHase and 24OHase genes[63].
Quantitative Real-Time was employed for that purpose. cDNA was constructed from
1μg of purified RNA and was used to quantify the message of the target genes. An
array of three housekeeping genes (RPL13A, GAPDH, β.actin) was used as an
internal control to normalize the data using the PCR array analysis software. RealTime Ct. values were converted to fold changes of a reference point, which was the
average Ct. of the control group. Data was analyzed using the one-way ANOVA
analysis, with subsequent Bonferroni multi group comparison. Groups with similar
letters were not significantly different from each other. Pvalue˂0.05 was considered
significant.
Vitamin D3 25-hydroxylase (CYP27A1) gene expression was analyzed in
tissue specimens. Gene expression data for VD3 25-OHase is shown in (Figure 3.3)
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and it suggest that the expression of this gene is significantly down-regulated in the
cancer tissue comparing to the non-cancerous tissue groups obtained from BCC
patients as well as from the controls. Both proximal and distal tissue groups are not
significantly different from each other. Despite the visual elevation of VD3 25-Ohase
message in the proximal and distal tissue groups comparing to the controls, the
differences were not statistically significant.
25-OH D3 1α-hydroxylase enzyme catalyzed the formation of 1α, 25 (OH)2
VD3, which is the hormonal form of vitamin D. this enzyme was shown to be
regulated at the transcription level [64]. Expression analysis of the gene encoding
this enzyme shows that the message is significantly up-regulated in the cancer and
the proximal tissue groups. The distal tissue specimens show a tendency to be
higher than the control group, but without a statistical significance (Figure 3.4).
Inactivation of the hormonal form of vitamin D3 occurs through a further
hydroxylation by the catabolism enzyme 1α, 25 (OH) 2 VD3 24-hydroxylase
(CYP24A1). Our data indicate that this gene is significantly down-regulated in the
distal tissue group comparing to other tissue groups. Cancer and proximal and
control tissue groups seem to retain similar message levels of this gene (Figure 3.5).
Analysis of vitamin D receptor (VDR) and its co-activators:
Vitamin D exerts its hormonal effect through activating a nuclear receptor
(VDR) which hetero-dimerizes with RXR. VDR-RXR heterodimer binds to specific
sequences of the DNA in the promoter region of the target genes called vitamin D
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response elements. Once that happens, two types of co-activator complexes (SRC
and DRIP) bind to VDR promoting the transcription initiation of the target gene [59].
Vitamin D receptor was studied at the gene message level and the protein
level in all tissue groups. Expression analysis of VDR gene shows that the cancer
tissue group has a significant up-regulation of VDR gene comparing to both the
proximal and the control tissue. VDR gene expression in the distal tissue group
shows tendency to be higher than the control, but lower than the cancer.
Statistically, the distal tissue group is not significantly different from any other tissue
group (Figure 3.6). VDR protein analysis in different tissue groups is shown in
(Figure 3.7). It reveals that VDR protein level in the cancer group is significantly
higher than other tissue groups. Proximal and distal are not significantly different
from each other or from the control group. In conclusion, both gene expression and
protein analysis indicate that BCC tissue contains higher levels of vitamin D
receptors than the cancer free tissue of the patients.
SRC is a protein complex that operates as a co-activator of VDR. It binds to
the receptor subsequent to its binding to the VDRE in the target gene’s promoter.
SRC possesses a histone-acetylase activity. Chromatin remodeling caused by SRC
makes the promoter region more accessible to other transcription factors. This
action is followed by the binding of DRIP complex which recruits components of the
transcription machinery in place[65]. We assessed the expression of the genes
encoding SRC and DRIP co-activator in BCC patients and the controls specimens.
Only the cancer tissue showed significant increase in the expression of SRC as
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compared to other tissue groups. SRC gene expression in the proximal and the
distal groups mimic the control group (Figure 3.8). Similarly, DRIP gene expression
in the cancer tissue was significantly higher than other tissue groups. No significant
differences were found in DRIP gene expression among proximal, distal, and control
tissue groups (Figure 3.9).
Studying the impact of VRD over-expression in BCC on mTOR pathway:
VDR is known to negatively regulate mTOR through impacting REDD1. The
latter gene is a VDR target gene that contains VDRE in its promoter. Up-regulation
of this gene is known to inhibit the activity of mTOR. VDR effect on its target gene
transcription regulation was shown to be impaired when VDREBP are up-regulated.
These proteins compete with VDR over the binding sites in the target genes
promoters [45]. We investigated whether the observed up-regulation of VDR in
cancer tissue is translated into reduction of mTOR signaling. For that purpose, we
studied some important proteins upstream and downstream of mTOR.
VDREBP protein levels analysis in all tissue groups is shown in Figure 3.11.
Our data shows that VDREBP protein levels are significantly elevated in the cancer
tissue comparing to the other groups. In contrast, the proximal tissue contains
significantly lower amounts of this protein than the other groups. The distal and the
control groups are not normal significantly different from each other.
REDD1 protein levels (Figure 3.10) reveal that the level of this protein in the
cancer group is significantly higher than in other tissue groups. The proximal tissue
tends to have a lower REDD1protein level than the distal and the control groups.
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However, the three groups (proximal, distal, and control) are not significantly
different from each other.
mTOR phosphorylates TIF4E-binding protein (4EBP), impairing its ability to
bind to TIF4E protein [43]. Level of 4EBP phosphorylation has been used as an
indicator for mTOR activity. Therefore, P-4EBP protein levels were assessed in
cancer and normal tissue of BCC patients and compared to the control group
(Figure 3.12). Results show that p-4EBP levels are significantly elevated in the
cancer tissue comparing to the control group. On the other hand, the proximal tissue
contains significantly lower amounts of this protein than the control. The distal tissue
is not significantly different from the control group.
Analysis of key genes up-stream of mTOR in (Ras- IP13-AKT-mTOR) pathway:
IP13-AKT-mTOR is one of the pathways that were reported to be upregulated in many cancers[66]. AKT is phosphorylated in two sites (S473 and Th
308). Both AKT phosphorylation sites are required to up-regulate mTOR activity.
Ras is an important oncogene upstream of this pathway and is recurrently reported
to have a gain of function mutation in many types of cancers [49].
Protein analysis shows that levels of AKT protein that are phosphorylated at
the location (S473) are significantly elevated in both cancer and proximal tissue. In
contrast, p-AKT (S473) levels in the distal and the control tissue groups are not
significantly different from each other (Figure 3.13). P-AKT (Th308) protein levels
were also detected in our tissue groups. Quantification of the exposed bands

51

indicated that levels of P-AKT phosphorylated at the location (Th308) follows the
same rend of p-AKT (S473) as shown in Figure 3.14.
The expression of KRas gene was also assessed in our tissue groups. KRas
mRNA was quantified using real-time PCR with KRas wild-type allele primers. Our
data suggest that KRas gene is up-regulated in all tissue groups obtained from BCC
patients comparing to the control group. However, we noticed that the expression
decreases as the location of the tissue specimen gets farther from the cancer
location. Statistically, KRas gene expression in the cancer and the proximal groups
is significantly higher than the control group but not than the distal tissue. The distal
tissue group is not significantly different from any other group including the control.
(Figure 3.15)
Detection of KRas point mutation in BCC issue samples using the ASB-PCR
technique:
Mutant allele specific real-time PCR with blocker ASB-PCR was used to
detect the presence of point mutations in KRas gene [51]. Specifically designed
primers were used to detect different possible point mutation that may occur in
cancer cells. Each mutant allele specific primer was used to detect the presence of
its corresponding point mutation in our tissue samples. Each ASB-PCR experiment
was repeated with and without the addition of the wild-type allele specific blocker to
minimize the non-specific amplification of the wild-type allele.
Tissue samples were inspected first for the presence of the point mutation
(mut 2.1) in KRas gene using (mut 2.1) allele specific forward primer(Figure 3.16).
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Results show that the message obtained using (mut 2.1) primer follows the same
trend obtained from the wild-type primer. The only significant difference observed
was in the cancer group in absence of the blocker. Upon adding the wild-type
specific blocker to the PCR reaction, the previously noted significant increase was
vanished. Our results suggest that the observed message is a non-specific
amplification of the wild-type allele, and we concluded that our samples do not have
(mut 2.1) Kras point mutation.
KRas point mutation (mut 4.1) was also tested in BCC tissue groups using
mutant allele specific (mut 4.1) primer. The analysis was performed with and without
adding the wild-type blocker. The message obtained using (mut 4.1) primer followed
the same previously described trend, without showing any statistical significant
among the groups neither with nor without the wild-type blocker. The results suggest
that the observed message is a non-specific amplification. In conclusion, no Kras
point mutation was detected by this mutant allele specific primer in our tissue
specimens (Figure 3.17).
The third KRas point mutation allele specific primer that was tested with our
samples was (mut 7.1) primer. The message generated by his primer also followed
the same trend obtained by the wild-type primer. No statistical significance was
found among the groups with or without the wild-type specific blocker. This indicated
that our samples are negative for the mutation detected by his mutant allele specific
primer (Figure 3.19).
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Finally, tissue specimens were tested using KRas mutant allele specific (mut
5.1) primer. The resulting message from this primer without adding the wild-type
specific blocker follows the same trend as the wild-type primer with no statistical
significance among tissue groups. Interestingly, upon adding the wild-type allele
specific blocker to the PCR reaction, all tissue groups from the BCC patients
(cancer, proximal, and distal) showed significantly higher message levels comparing
to the control group. Our data suggest the presence of this Kras point mutation in
cancer, proximal and distal tissue specimens excised from BCC patients (Figure
3.18).
Gli1 gene expression analysis as an indicator of Hedge-hog pathway activity:
Expression of Gli1 gene was quantified in tissue specimens as an indicator of
Hh-Gli pathway signaling. Our data clearly revealed that cancer tissue has a
significantly higher expression of Gli1 gene compared to the other groups. This
result indicates higher activity of Hh-Gli pathway in the cancer tissue, despite the
higher vitamin D receptor and activation genes in that tissue groups. Proximal and
distal tissue groups showed Gli1 gene expression that mimics the control group
(Figure 3.20).
Analysis of P53-MDM2 pathway:
P53 is an important tumor suppressor gene in the cell. It is known to be
regulated through MDM2. Elevated level of p53 protein promotes up-regulation of
MDM2, which in turn binds and inactivates p53. There is emerging evidence in
literature suggesting VDR involvement in this regulation [67]. VDR gene was found
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to contain a p53 response element in its promoter. On the other hand, MDM2
promoter contains both VDR and P53 response elements [67, 68].
Expression of P53 gene was quantified and compared among different tissue
groups. Our data shows that cancer tissue has a significantly higher message of
P53 gene comparing to all other groups. The Proximal and the distal groups are not
significantly different from each other or from the control in regards to p53 gene
expression (Figure 3.21).
Similarly, MDM2 gene expression analysis (Figure 3.22) proposes that the
cancer tissue show significantly higher expression comparing to other tissues.
Proximal and distal groups show slightly lower MDM2 expression than the control
group, but the differences are not statistically significant.
Analysis of VEGF gene expression in BCC tissue specimens:
Vascular endothelial growth factor (VEGF) gene is VDR target gene, and it
contains VDRE in its promoter [69, 70]. Up-regulation of this protein causes vascular
growth which triggers angiogenesis around the cancer, which promotes tumor
growth [70].
Expression Analysis of VEGF gene was carried out in BCC tissue groups as
well as the control group (Figure 3.23). Our results propose that tissue specimens
from the cases generally up-regulate VEGF gene comparing to the controls. The
elevation in VEGF gene expression is statistically significant only in the proximal
tissue group despite the visual trend of higher message of VEGF in the cancer
tissue as well.
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Gene expression analysis of important cell regulators:
Caspase-3, apoptosis-related cysteine peptidase-3, is a key enzyme in
controlling the programmed cell death, and it is involved in both intrinsic and
extrinsic apoptosis pathways[71]. Expression of caspase-3 gene was analyzed in
BCC tissue groups (Figure 3.25). Data analysis discloses a significant up-regulation
of caspase-3 gene message in the cancer tissue comparing to all other tissue
groups. We observed a trend of gradual decrease among the tissue specimens from
the cases, inferring an inverse relationship between caspase-3 message and the
distance from the cancer location. In other words, Caspase-3 message in the
proximal tissue is significantly lower than in the cancer, and significantly higher than
in the distal tissue. Yet, the proximal and the distal groups are not statistically
significant from the control group.
Bcl-2 protein is an anti-apoptotic protein that halts the intrinsic (mitochondrial)
apoptosis pathway through blocking the release of cytochrome C from the
mitochondria [72]. Gene expression analysis of our groups proposes a dramatic
elevation in the Bcl2 message in the cancer tissue comparing to the other groups.
Proximal and distal tissue specimens are slightly higher than the control, but not
significantly different from it (Figure 3.24).
PARP-1 is a chromatin associated protein, and is important for cell survival
and growth. PARP-1 plays an important role in DNA repair pathways especially the
BER, and function as a transcription regulator for some genes [73]. The expression
and the cleavage of PARP-1 were both found to be down-regulated by vitamin D3
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[34, 69, 73, 74]. The message of PARP-1 gene was quantified in our tissue
specimens (Figure 3.26). Data clearly reveals that the cancer tissue has significantly
higher expression of PARP-1 gene comparing to the other tissue groups. Proximal
and distal tissue has PARP-1 gene expression similar to that in the control group.
Apex-1 gene expression was also analyzed as another gene involved in DNA
repair. Our results indicate that Apex-1 gene is significantly down-regulated in the
proximal and distal comparing to the cancer and the control. Interestingly, the
expression of this gene in the cancer tissue group mimics that in the control group
(Figure 3.27).
Expression analysis of GADD45A gene (growth arrest and DNA-damageinducible protein alpha) also indicates higher message in the cancer tissue than all
other groups. Data analysis discloses a general up-regulation of GADD45A gene in
all tissue specimens obtained from BCC patients compared to the control. This upregulation is greater in the cancer tissue, with a trend of a gradual decline with the
increasing distance from the cancer. GADD45A message levels in the cancer and
the proximal tissue are significantly higher than the control. The distal group
message level falls between the proximal group and the control, but it is not
significantly different from any of them (Figure 3.28).
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Table 3.1: Demographic data analysis for BCC Patients: participants are 20
Caucasian BCC patients from southeast Michigan. Patients are 14 men and 6
women of age range between (43-89 years old). Average age is 74 years; median
age and mode are both at 80 years. Ages of men and women are not significantly
different from each other. Participants’ age data failed to pass the KS normality test.
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Subjects Ages

Males

Females

All BCC

Sample size (N)

14

6

20

Mean age

74.357

74.667

74.45

Standard deviation (SD)

12.555

11.518

11.949

Std. error of mean(SEM)

3.356

4.944

2.741

Lower 95% conf. limit

67.109

61.622

68.858

Upper 95% conf. limit

81.605

87.045

80.042

Minimum age

43

56

43

Median age (50th percentile)

80

77.5

80

Maximum age

89

86

89

Normality test KS

0.3163

Normality test P value

0.0005

Passed normality test?

No

Participants Race

All participants are Caucasian
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Figure 3.1: Ages of BCC patients at time of diagnosis is not normally
distributed: BCC patients were grouped based on their ages at time of diagnosis.
Each group covers 10 years within the patient’s age range as the following: ≤45, 4655, 56-65, 66-75, 76-85, and 86-90. The number of patients in each group was
plotted at the middle of group. The trend line shows a peak at (76-85 Y/O) group
with a gradual increase before 75 Y/o and a sharp decline after 85 Y/o causing the
skewed distribution.
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Figure 3.2: RNA integrity gel: denaturing RNA gel electrophoresis image for
cancer, proximal and distal samples taken from the same patient. Cancer tissue
yielded 2.5 times as much RNA as the same weight of the normal tissue excised
from the same person at the same time. Density of the bands is a quantity indicator.
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Figure 3.3: Vitamin D activation gene Vitamin D3 25-hydroxylase (CYP27A1)
expression analysis in BCC Patients’ tissue: Data suggests that expression of VD3
25-OHase is significantly down regulated in basal cell carcinoma tissue comparing
to normal tissue obtained from BCC patients as well as from the controls. Both
proximal and distal tissue groups are not significantly different from each other.
Despite the visual elevation of VD3 25-Ohase message in the normal tissue of the
patients comparing to the controls, the difference was not statistically significant.
cDNA was constructed from 1μg of purified RNA and used to quantify the message
of VD3 25-OHase gene which performs the first step of VD activation yielding
25(OH)VD3. mRNA was quantified by real-time PCR and expressed as fold change
of the controls group average. a) Results shown in column representing groups
averages and SEMs. b) Individual data points presented as scatter plots, error bars
show the mean and the SEM for each tissue group. Data was analyzed by one-way
ANOVAs analysis with subsequent Bonferroni’s multi group comparison. Groups
with similar letters are not significantly different from each other. Pvalue≤0.05 is
considered significant.
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Figure 3.4: 25-Hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1)
expression analysis in all tissue groups: cDNA was constructed from 1μg of purified
RNA and used to quantify the message of the vitamin D activation gene (VD3 1αhydroxylase). mRNA was quantified by real-time PCR expressed as fold changes of
the controls group average. Data shows that the message of VD3 1α-hydroxylase
which performs the final step of activation of vitamin D and forming the hormonal
form of it is significantly elevated in both the cancer and the proximal tissue groups
comparing to the proximal and the control groups. The proximal tissue specimens
show a clear tendency to be higher than the controls with no statistical significance.
a) Results shown in column representing groups averages and SEMs. b) Individual
data points presented as scatter plots, error bars show the mean and the SEM for
each tissue group. Data was analyzed by one-way ANOVAs analysis with
subsequent Bonferroni’s multi group comparison. Groups with similar letters are not
significantly different from each other. Pvalue≤0.05 is considered significant.
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Figure 3.5: Vitamin D3 catabolism gene 1α, 25 (OH)2 VD3 24-hydroxylase
(CYP24A1) expression analysis in BCC patients tissue groups: 1μg of purified RNA
from different tissue specimens were used to construct cDNA, which was in turn
used to quantify the message of the gene. mRNA of 1α,25(OH)2VD3 24-OHase
gene was quantified in tissue specimens using real-time PCR and was expressed as
fold changes of the controls group average. Our data clearly reveals that the distal
tissue group obtained from BCC patients significantly down-regulates VD3
catabolism gene comparing to other tissue groups. Cancer tissue itself along with
the proximal tissue retains normal VD3 catabolism gene activity, showing no
significant difference from the control group. a) Results shown in column
representing groups averages and SEMs. b) Individual data points presented as
scatter plots, error bars show the mean and the SEM for each tissue group. Data
was analyzed by one-way ANOVAs analysis with subsequent Bonferroni’s multi
group comparison. Groups with similar letters are not significantly different from
each other. Pvalue≤0.05 is considered significant.
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Figure 3.6: Vitamin D receptor (VDR) protein analysis in tissue groups:
Whole cell extract was prepared using RIPA buffer, and then used to quantify VDR
protein levels in tissue samples. Western blot was performed by running all groups
on 10% SDS-PAGE before targeted bands were plotted by specific anti-bodies.
β.actin protein level was used as an internal control. Quantifying the exposed bands
reveals that VDR protein level in the cancer group is significantly higher than those
in other tissue groups. Proximal and distal are not significantly different from each
other or from the control group. Data was analyzed by one-way ANOVAs analysis
with subsequent Bonferroni’s multi group comparison. a) Image of the quantified
western blot bands for VDR and β.actin. b) Results shown in column representing
the average and the SEM for each tissue group. Groups with similar letters are not
significantly different from each other. Pvalue≤0.05 is considered significant
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Figure 3.7: Vitamin D receptor VDR gene expression analysis in tissue
groups: expression analysis in all tissue groups: cDNA was constructed from 1μg of
purified RNA and used to quantify the message of vitamin D receptor (VDR) gene.
mRNA of VDR was quantified by real-time PCR and expressed as fold change of
the controls group average. Data analysis shows that the cancer tissue group has a
significant up-regulation of VDR gene comparing to both the proximal and the
control tissue. In contrast to the proximal tissue, the distal tissue group shows
tendency to be higher than the normal, but lower than the cancer. The distal tissue
group is not statistically significantly different from any other tissue group. a) Results
shown in column representing groups averages and SEMs. b) Individual data points
presented as scatter plots, error bars show the mean and the SEM for each tissue
group. Data was analyzed by one-way ANOVAs analysis with subsequent
Bonferroni’s multi group comparison. Groups with similar letters are not significantly
different from each other. Pvalue≤0.05 is considered significant.
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Figure 3.8: Comparison of VDR Co-activator (SRC) gene expression among
tissue groups: cDNA was constructed from 1μg of purified RNA and used to quantify
the message of VDR co-activator SRC gene, which was then quantified by real-time
PCR and expressed as fold change of the controls average. Only the Basal cell
carcinoma tissue shows significantly elevated expression of SRC comparing to the
normal tissue from BCC patients and from the controls. Proximal and distal tissue
groups have normal SRC expression that mimics the control group. a) Results
shown in column representing groups averages and SEMs. b) Individual data points
presented as scatter plots, error bars show the mean and the SEM for each tissue
group. Data was analyzed by one-way ANOVAs analysis with subsequent
Bonferroni’s multi group comparison. Groups with similar letters are not significantly
different from each other. Pvalue≤0.05 is considered significant.
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Figure 3.9: Analysis of DRIP (VDR Co-activator) gene expression among
tissue groups: 1μg of purified RNA from different tissue specimens were used to
construct cDNA, which was in turn used to quantify the message of the gene. mRNA
of VDR co-activator DRIP gene was quantified in tissue specimens using real-time
PCR and was expressed as fold changes of the controls group average. Our data
clearly reveals that BCC patients’ cancer tissue shows significantly higher
expression of DRIP comparing to the normal tissue from BCC patients and from the
controls. Proximal and distal tissue groups have normal DRIP expression that
mimics the control group. a) Results shown in column representing groups averages
and SEMs. b) Individual data points presented as scatter plots, error bars show the
mean and the SEM for each tissue group. Data was analyzed by one-way ANOVAs
analysis with subsequent Bonferroni’s multi group comparison. Groups with similar
letters are not significantly different from each other. Pvalue≤0.05 is considered
significant.
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Figure 3.10: Protein Levels of vitamin D response element binding protein
VDREBP: Whole cell extract was prepared using RIPA buffer, and then used to
quantify VDREBP protein levels in tissue samples. Western blot was performed by
running all groups on 10% SDS-PAGE before targeted bands were plotted by
specific anti-bodies. β.actin protein level was used as an internal control. Results
show that VDREBP protein levels are significantly elevated in the basal cell
carcinoma tissue. In contrast to the cancer tissue, the normal tissue proximal to the
cancer location contains extremely low amounts of this protein. The normal tissue
that is distal to the cancer shows normal levels of this protein that is not significantly
different from the control group. Data was analyzed by one-way ANOVAs analysis
with subsequent Bonferroni’s multi group comparison. a) Image of the quantified
western blot bands for VDREBP and β.actin. b) Results shown in column
representing the average and the SEM for each tissue group. Groups with similar
letters are not significantly different from each other. Pvalue≤0.05 is considered
significant
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Figure 3.11: Assessment of REDD1 (mTOR blocker) protein levels in BCC
patients’ tissue: Whole cell extract was prepared using RIPA buffer, and then used
to quantify REDD1 protein levels in tissue samples. Western blot was performed by
running all groups on 10% SDS-PAGE before targeted bands were plotted by
specific anti-bodies. β.actin protein level was used as an internal control. Quantifying
the exposed bands reveals that REDD1 protein level in the cancer group is
significantly higher than those in other tissue groups. Proximal tissue group shows a
visible trend to have lower protein levels of REDD1 than the distal and the control
groups. However, statistical analysis did not confirm any significant differences
between the normal tissue from BCC patients and the controls. Data was analyzed
by one-way ANOVAs analysis with subsequent Bonferroni’s multi group comparison.
β.actin protein level was used as an internal control. . a) Image of the quantified
western blot bands for REDD1 and β.actin. b) Results shown in column representing
the average and the SEM for each tissue group. Groups with similar letters are not
significantly different from each other. Pvalue≤0.05 is considered significant
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Figure 3.12: Assessment of p-4EBP Protein Levels in cancer and normal
tissue of BCC patients as compared to the controls: Whole cell extract was prepared
using RIPA buffer, and then used to quantify p-4EBP protein levels in tissue
samples. Western blot was performed by running all groups on 10% SDS-PAGE
before targeted bands were plotted by specific anti-bodies. β.actin protein level was
used as an internal control. Results show that p-4EBP protein levels are significantly
elevated in the cancer tissue comparing to the control group. On the other hand, the
normal tissue obtained from BCC patients that is proximal to the cancer location
contains extremely low amounts of this protein. The normal tissue that is distal to the
cancer shows normal levels of this protein that is not significantly different from the
control group. Data was analyzed by one-way ANOVAs analysis with subsequent
Bonferroni’s multi group comparison. a) Image of the quantified western blot bands
for p-4EBP and β.actin. b) Results shown in column representing the average and
the SEM for each tissue group. Groups with similar letters are not significantly
different from each other. Pvalue≤0.05 is considered significant
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Figure 3.13: p-AKT (S473) protein analysis in all tissue groups: Whole cell
extract was prepared using RIPA buffer, and then used to quantify p-AKT (S473)
protein levels in different tissue samples. Western blot was performed by running all
groups on 10% SDS-PAGE before targeted bands were plotted by specific antibodies. β.actin protein level was used as an internal control. Protein analysis on
tissue specimens obtained from BCC patients shows that levels of AKT protein
phosphorylated at the location (S473) are significantly elevated in both cancer tissue
and normal tissue adjacent to the cancer as compared to the control group. In
contrast, p-AKT (S473) levels in the normal distal tissue from BCC patients and the
normal tissue obtained from the controls are not significantly different from each
other. Data was analyzed by one-way ANOVAs analysis with subsequent
Bonferroni’s multi group comparison. a) Image of the quantified western blot bands
for p-AKT(S473) and β.actin. b) Results shown in column representing the average
and the SEM for each tissue group. Groups with similar letters are not significantly
different from each other. Pvalue≤0.05 is considered significant
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Figure 3.14: p-AKT (Th308) protein levels in BCC tissue groups and the
control group: Whole cell extract was prepared using RIPA buffer, and then used to
quantify p-AKT (Th308) protein levels in tissue specimens. Western blot was
performed by running all groups on 10% SDS-PAGE before targeted bands were
plotted by specific anti-bodies. β.actin protein level was used as an internal control.
Quantification of the exposed bands indicates that levels of AKT protein
phosphorylated at the location (Th308) follows the same rend of p-AKT (S473).
Statistical analysis of the data suggests that levels of p-AKT (Th308) are significantly
elevated in cancer tissue and proximal normal tissue comparing to the controls. In
contrast, levels of this protein in the normal distal tissue and the control group are
not significantly different from each other. Data was analyzed by one-way ANOVAs
analysis with subsequent Bonferroni’s multi group comparison. a) Image of the
quantified western blot bands for p-AKT (Th308) and β.actin. b) Results shown in
column representing the average and the SEM for each tissue group. Groups with
similar letters are not significantly different from each other. Pvalue≤0.05 is
considered significant
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Figure 3.15: KRas wild type gene expression in different tissue groups:
cDNA was constructed from 1μg of purified RNA and used to quantify the message
of vitamin D receptor KRas gene. mRNA was quantified using real-time PCR assay
with KRas wild-type allele primers, and results were expressed as fold changes of
the controls group average. Analysis of the wild-type KRas gene expression reveals
that KRas is up-regulated in all tissue groups obtained from BCC patients. The
observed elevation gradually decreases in relation to the distance of the tissue
specimen from the cancer. Statistically, KRas expression is significantly higher in
cancer and proximal tissue groups than the control group but not than the distal
tissue. The later tissue group is not statistically significantly different from any other
group including the control. a) Results shown in column representing groups
averages and SEMs. b) Individual data points presented as scatter plots, error bars
show the mean and the SEM for each tissue group. Data was analyzed by one-way
ANOVAs analysis with subsequent Bonferroni’s multi group comparison. Groups
with similar letters are not significantly different from each other. Pvalue≤0.05 is
considered significant.
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Figure 3.16: Detection of (mut 2.1) KRas point mutation in BCC tissue
groups: mutant allele specific real-time PCR with/without blocker was used to
detect the presence of (mut 2.1) mutation in all tissue groups. cDNA was
constructed from 1μg of purified RNA and used to quantify the message of KRas
mutation using allele specific (mut 2.1) PCR forward primer and the wild-type
reverse primer. The analysis was performed for each tissue group with and
without adding wild-type allele blocker to the PCR reaction for comparison.
mRNA was quantified expressed as fold change of the controls group average.
Results shows that the message obtained using (mut 2.1) primer follows the
same trend obtained by the wild-type primer with the absence of the significance
except for the cancer group which shows significant increase in the message
level without using the wild type blocker. Upon adding the wild-type allele blocker
to the PCR reaction the previously mentioned significance disappeared
suggesting that the observed message is non-specific amplification of the wildtype allele and no (mut 2.1) KRas point mutation was detected in BCC tissue
specimens. a) Results shown in column representing groups averages and
SEMs. b) Individual data points presented as scatter plots, error bars show the
mean and the SEM for each tissue group. Data was analyzed by one-way
ANOVAs analysis with subsequent Bonferroni’s multi group comparison. Groups
with similar letters are not significantly different from each other. Pvalue≤0.05 is
considered significant.
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Figure 3.17: Detection of (mut 4.1) KRas point mutation in BCC tissue
groups: mutant allele specific real-time PCR with/without blocker was used to
detect the presence of (mut 4.1) mutation in all tissue groups. cDNA was
constructed from 1μg of purified RNA and used to quantify the message of KRas
mutation using allele specific (mut 4.1) PCR forward primer and the wild-type
reverse primer. The analysis was performed for each tissue group with and
without adding wild-type allele blocker to the PCR reaction for comparison.
mRNA was quantified expressed as fold change of the controls group average.
The message obtained using (mut 4.1) primer follows the same trend obtained
the wild-type primer without showing any statistical significant among the groups
neither with nor without the wild-type specific blocker. The results suggest that
the observed message is non-specific amplification of the wild-type allele and no
(mut 4.1) KRas point mutation was detected in BCC tissue specimens. a) Results
shown in column representing groups averages and SEMs. b) Individual data
points presented as scatter plots, error bars show the mean and the SEM for
each tissue group. Data was analyzed by one-way ANOVAs analysis with
subsequent Bonferroni’s multi group comparison. Groups with similar letters are
not significantly different from each other. Pvalue≤0.05 is considered significant.
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Figure 3.18: Detection of (mut 7.1) KRas point mutation in BCC tissue
groups: mutant allele specific real-time PCR with/without blocker was used to
detect the presence of (mut 7.1) mutation in all tissue groups. cDNA was
constructed from 1μg of purified RNA and used to quantify the message of KRas
mutation using allele specific (mut 7.1) PCR forward primer and the wild-type
reverse primer. The analysis was performed for each tissue group with and
without adding wild-type allele blocker to the PCR reaction for comparison.
mRNA was quantified expressed as fold change of the controls group average.
The message obtained using (mut 7.1) primer follows the same trend obtained by
the wild-type primer without showing any statistical significant among the groups
neither with nor without the wild-type specific blocker. The results suggest that
the observed message is non-specific amplification of the wild-type allele and no
(mut 7.1) KRas point mutation was detected in BCC tissue specimens. a) Results
shown in column representing groups averages and SEMs. b) Individual data
points presented as scatter plots, error bars show the mean and the SEM for
each tissue group. Data was analyzed by one-way ANOVAs analysis with
subsequent Bonferroni’s multi group comparison. Groups with similar letters are
not significantly different from each other. Pvalue≤0.05 is considered significant.

2.5

B+
BB+

b)

B+
BB+

BB+

D
is
ta
l

B-

al

0
B+

ox
im

0

Pr

0.5

a

r

1

A

Ca
nc
e

1.5

ro
l

KRas Mut 7.1 mRNA
Fold Change /Control's Average

a)

Co
nt

KRas mut 7.1 mRNA levels
Fold Change/Control's average

94

KRas Mut 7.1

3.5
3

a

A
a

2

A
a

A

B-

Tissue From BCC Patients

6

4

2

B-

Tissue from BCC Patients
B+
B-

B+
B-

95

Figure 3.19: Detection of (mut 5.1) KRas point mutation in BCC tissue
groups: mutant allele specific real-time PCR with/without blocker was used to
detect the presence of (mut 5.1) mutation in all tissue groups. cDNA was
constructed from 1μg of purified RNA and used to quantify the message of KRas
mutation using allele specific (mut 5.1) PCR forward primer and the wild-type
reverse primer. The analysis was performed for each tissue group with and
without adding wild-type allele blocker to the PCR reaction for comparison.
mRNA was quantified expressed as fold change of the controls group average.
The message obtained using (mut 5.1) primer without wild-type specific blocker
follows the same trend as the wild-type primer with no statistical significance
among the tissue groups. Upon adding the wt. blocker to the PCR reaction, all
tissue groups of the BCC patients show significant increase in the message of
(mut 5.1) mutant allele comparing to the control group. Results suggest the
presence of KRas point mutation (mut 5.1) in cancer, proximal and distal tissue
specimens excised from BCC patients. a) Results shown in column representing
groups averages and SEMs. b) Individual data points presented as scatter plots,
error bars show the mean and the SEM for each tissue group. Data was
analyzed by one-way ANOVAs analysis with subsequent Bonferroni’s multi group
comparison. Groups with similar letters are not significantly different from each
other. Pvalue≤0.05 is considered significant.
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Figure 3.20: Analysis of Gli1 gene expression among tissue groups: 1μg of
purified RNA from different tissue specimens were used to construct cDNA, which
was in turn used to quantify the message of the gene. mRNA of Gli1 gene was
quantified in tissue specimens using real-time PCR and was expressed as fold
changes of the controls group average. Our data clearly reveals that BCC patients’
cancer tissue shows significantly higher expression of Gli1 comparing to the normal
tissue from BCC patients and from the controls indicating higher activity of hedgehog pathway in the cancer tissue. Proximal and distal tissue groups have normal
Gli1 expression that mimics the control group. a) Results shown in column
representing groups averages and SEMs. b) Individual data points presented as
scatter plots, error bars show the mean and the SEM for each tissue group. Data
was analyzed by one-way ANOVAs analysis with subsequent Bonferroni’s multi
group comparison. Groups with similar letters are not significantly different from
each other. Pvalue≤0.05 is considered significant.
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Figure 3.21: Expression Analysis of tumor suppressor gene P53 in BCC
tissue groups: mRNA of P53 gene was quantified in tissue specimens using realtime PCR. 1μg of purified RNA from different tissue specimens were used to
construct cDNA, which was in turn used to quantify the message of the gene. Data
was expressed as fold changes of the controls group average. Our data clearly
reveals that BCC patients’ cancer tissue shows significantly higher expression of
P53 comparing to the normal tissue from BCC patients as well as to the controls.
Proximal and distal tissue groups have P53 expression is not significantly different
from the control tissue group. a) Results shown in column representing groups
averages and SEMs. b) Individual data points presented as scatter plots, error bars
show the mean and the SEM for each tissue group. Data was analyzed by one-way
ANOVAs analysis with subsequent Bonferroni’s multi group comparison. Groups
with similar letters are not significantly different from each other. Pvalue≤0.05 is
considered significant.
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Figure 3.22: MDM2 gene expression Analysis in experimental tissue groups:
mRNA of MDM2 gene was quantified in tissue specimens using real-time PCR. 1μg
of purified RNA from different tissue specimens were used to construct cDNA, which
was used to quantify the message of the gene. Data was expressed as fold changes
of the controls group average. Results analysis proposes that basal cell carcinoma
tissue obtained from our cases show significantly higher expression of MDM2
comparing to the normal tissue from BCC patients as well as to the controls.
Proximal and distal tissue groups show a slight decrease in MDM2 expression but it
is not statistically significantly from the control group. a) Results shown in column
representing groups averages and SEMs. b) Individual data points presented as
scatter plots, error bars show the mean and the SEM for each tissue group. Data
was analyzed by one-way ANOVAs analysis with subsequent Bonferroni’s multi
group comparison. Groups with similar letters are not significantly different from
each other. Pvalue≤0.05 is considered significant.
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Figure 3.23: Vascular endothelial growth factor (VEGF) gene expression
Analysis in BCC tissue groups: mRNA of VEGF gene was quantified in tissue
specimens using real-time PCR. cDNA was constructed from 1μg of purified RNA
from different tissue specimens, and was used to quantify the message of the gene.
Data was expressed as fold changes of the controls group average. Results
propose that basal cell carcinoma tissue obtained from our cases show upregulation of VEGF gene expression comparing to the controls. The elevation in
VEGF expression is statistically significant only in the proximal tissue group despite
the visual trend of higher message of VEGF in the cancer tissue group a) Results
shown in column representing group’s averages and SEMs. b) Individual data points
presented as scatter plots, error bars show the mean and the SEM for each tissue
group. Data was analyzed by one-way ANOVAs analysis with subsequent
Bonferroni’s multi group comparison. Groups with similar letters are not significantly
different from each other. Pvalue≤0.05 is considered significant.
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Figure 3.24: Gene expression analysis of caspase 3, apoptosis-related
cysteine peptidase in BCC tissue groups: cDNA was constructed from 1μg of
purified RNA and used to quantify the message of caspase-3 gene. mRNA of
caspase-3 was quantified by real-time PCR and expressed as fold change of the
controls group average. Data analysis discloses a significant up-regulation of
caspase-3 gene message level in the cancer tissue comparing to all other tissue
groups. A trend of gradual decrease was observed in the normal tissue of the
patients in relation to the distance of the specimen from the cancer location.
Caspase-3 message level in the proximal tissue is significantly lower than in the
cancer, and the level in the distal tissue is significantly lower than in the proximal.
Despite the significant difference between the proximal and the distal groups,
they both are not statistically significant from the control group. a) Results shown
in column representing groups averages and SEMs. b) Individual data points
presented as scatter plots, error bars show the mean and the SEM for each
tissue group. Data was analyzed by one-way ANOVAs analysis with subsequent
Bonferroni’s multi group comparison. Groups with similar letters are not
significantly different from each other. Pvalue≤0.05 is considered significant.
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Figure 3.25: Expression analysis of the anti-apoptotic gene Bcl2 in BCC
tissue groups: cDNA was constructed from 1μg of purified RNA and used to
quantify the message of Bcl2 gene. mRNA of VDR was quantified by real-time
PCR and expressed as fold change of the controls group average. Data
proposes a dramatic elevation in the anti-apoptotic gene Bcl2 message level in
the cancer tissue comparing to all other tissue groups. The normal tissue excised
from BCC patients is slightly higher, but not statistically significant, than the
control tissue. a) Results shown in column representing groups averages and
SEMs. b) Individual data points presented as scatter plots, error bars show the
mean and the SEM for each tissue group. Data was analyzed by one-way
ANOVAs analysis with subsequent Bonferroni’s multi group comparison. Groups
with similar letters are not significantly different from each other. Pvalue≤0.05 is
considered significant.
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Figure 3.26: Expression analysis PARP-1 gene in BCC tissue groups: 1μg of
purified RNA from different tissue specimens were used to construct cDNA, which
was in turn used to quantify the message of the gene. mRNA of PARP-1 gene was
quantified in tissue specimens using real-time PCR and was expressed as fold
changes of the controls group average. Our data clearly reveals that BCC patients’
cancer tissue shows significantly higher expression of PARP-1 comparing to the
normal tissue from BCC patients and from the controls indicating higher DNA repair
activity in the cancer tissue. Proximal and distal tissue groups have normal PARP-1
expression that mimics the control group. a) Results shown in column representing
groups averages and SEMs. b) Individual data points presented as scatter plots,
error bars show the mean and the SEM for each tissue group. Data was analyzed
by one-way ANOVAs analysis with subsequent Bonferroni’s multi group comparison.
Groups with similar letters are not significantly different from each other.
Pvalue≤0.05 is considered significant.
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Figure 3.27: Apex-1 gene expression analysis in BCC tissue groups:
Expression analysis Apex-1 gene in was measure using Real-time PCR. 1μg of
purified RNA from different tissue specimens were used to construct cDNA, which
was in turn used to quantify the message of the gene. mRNA of Apex-1 gene was
quantified expressed as fold changes of the controls group average. Data clearly
shows that Apex-1 gene is significantly down-regulated in normal tissue obtained
from BCC patients. The expression of this gene is, interestingly, equally reduced in
the proximal and distal locations. Cancer tissue itself maintains normal expression of
this gene as the message levels in the cancer group mimic those of the controls. a)
Results shown in column representing groups averages and SEMs. b) Individual
data points presented as scatter plots, error bars show the mean and the SEM for
each tissue group. Data was analyzed by one-way ANOVAs analysis with
subsequent Bonferroni’s multi group comparison. Groups with similar letters are not
significantly different from each other. Pvalue≤0.05 is considered significant.
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Figure 3.28: Expression analysis of the growth arrest and DNA-damageinducible protein alpha GADD45A: cDNA was constructed from 1μg of purified
RNA and used to quantify the message of GADD45A gene. mRNA was
quantified by real-time PCR and expressed as fold change of the controls group
average. Data analysis discloses a general up-regulation of GADD45A gene
message level in BCC patients’ tissue groups comparing to the controls. The upregulation is the greatest in the cancer tissue group with a trend of gradual
decline in the message level in the tissue with the increasing distance from the
cancer. GADD45A message level in the cancer and the proximal tissue is
significantly higher than the control. The distal group message level falls between
the proximal and control making it statistically not significantly different from any
of the two groups. a) Results shown in column representing groups averages and
SEMs. b) Individual data points presented as scatter plots, error bars show the
mean and the SEM for each tissue group. Data was analyzed by one-way
ANOVAs analysis with subsequent Bonferroni’s multi group comparison. Groups
with similar letters are not significantly different from each other. Pvalue≤0.05 is
considered significant.
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CHAPTER 4: DISCUSSION AND CONCLUSION
The relation between Vitamin D status and the onset and progression of nonmelanoma skin cancer-NMSC is not clear. Most of the published human studies
about vitamin D and NMSC are epidemiological, correlational, and controversial;
thus they do not address causality. For example, some studies showed beneficial
influence of vitamin D supplementation on onset and progression of NMSC while
others suggested adverse impact of vitamin D, and sometimes lack of association
was concluded [28, 29, 32].
Mechanistic studies on BCC are few, and mostly performed using cell-lines or
animal models. These approaches give rise to problems related to generalizing the
findings to other experimental models. This study is unique for its mechanistic
approach while using human tissues taken from NMSC patients and control
individuals. Also, comparing three groups of normal tissue- proximal, distal, and
control- is a novel approach.
Cases and controls were recruited in Henry Ford Hospital after obtaining the
required approvals. Cases are 20 basal cell carcinoma patients from south east
Michigan, controls are 6 individuals who were never diagnosed with cancer from the
same geographic area. This reduces the differences between the two groups in
exposure to environmental factors. Cases are 14 Caucasian males and 6 Caucasian
females, and their age ranges between 46 and 89 years with average age of 74.
Cases are 6 women who were pre-scheduled for eyelid-lift surgery, and age more
than 50 years. Age of the control subjects ranges between 50 and 69. Ages of the
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cases and controls are not an exact match, but it was the closest we could achieve.
Unfortunately, our group could not successfully recruit male subjects among the
controls despite the attempts. All patients were diagnosed with BCC in the head and
nick area. Therefore, all cases and controls specimens were excised from locations
that are exposed to sun. Also, With the exception of BCC diagnoses, all inclusion
and exclusion criteria were similarly applied in recruiting both cases and controls.
Interestingly, while the race of the subjects were not pre-determined. However, this
was an advantage design as it eliminated variations among participants due to race
differences.
The trend line for age distribution at time of diagnosis shows gradual increase
of number of cases diagnosed with the increasing age after 55 years of age, and
rapid decline after 85 years of age. About 50% of the cases are between 75-85
years old. We suggest that this can be partially due to the drop in the population
after that age. The skewed peak is harmonious with the result of the normality test.
KS test result suggested that age data is not normally distributed.
Upon isolating total RNA from tissue samples, we observed higher yield of
RNA per milligram of tissue from the cancer tissue comparing to normal tissue from
BCC patients as well as tissue from controls. This can possibly be related to the
histology of BCC tissue. This type of cancer cells has hyper-chromatic nucleus
surrounded by a small amount of cytoplasm [11] implying higher activity in the
nucleus and larger proportion of nuclei to the cell volume.
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To understand metabolism of vitamin D in BCC tumors and normal tissue
from cases as well as from control subjects, we analyzed the expression of the key
genes in vitamin D metabolism. The first step of activating Vitamin D3 precursors is
carried out by VD3 25-hydroxylase (CYP27A1) forming 25(OH) VD3, which is the
main form of vitamin D in the body [75]. The hormonal form of vitamin D is 1α, 25
(OH) 2 VD3, and its formation is catalyzed by 25-Hydroxyvitamin D3 1-alphahydroxylase (CYP27B1) gene. 25(OH) VD3 1α-OHase is considered a renal
enzyme, but it is also expressed in other tissues including keratinocytes [26].
Interestingly, in cancer tissue, the expression of VD3 25-hydroxylase is
significantly down regulated, while VD3 1α-OHase, which performs the final step of
activation, is over expressed. Cells adjacent to the cancer up regulate both
activation enzymes. Distal tissue shows significant increases only in VD3 25-OHase
expression. Over expression of VD3 1α-OHase in and around the cancer location is
not a surprising. This gene was shown to be up regulated in keratinocytes by factors
like TNF-α and INF-γ even in conditions other than cancer [76]. We propose the that
normal tissue of the BCC patients increases the local availability of 1α-OHase
substrate , while the cancer tissue and its feeding cells increase the activation of the
hormonal vitamin D. Studies have provided evidence that 1α-OHase is
transcriptionally regulated. For instance, MCF-7 cells overexpressing 1α-OHase
gene could locally activate vitamin D analogs and exert the transcription effect of
VDR [26]. Besides, others have demonstrated that renal 1α-OHase is being
regulated by different positive and negative regulators at the transcription level[64].
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Further hydroxylation by the catabolism enzyme VD3 24-hydroxylase
(CYP24A1) inactivates VD3 [39, 77]. Analyses of this gene suggest that distal tissue
maintains lower expression of this enzyme as compared to other tissue groups.
Ligand-bound VDR, is a transcription factor that regulates the transcription of
several target genes [59, 78]. Upon hetero-dimer zing with RXR[65], VDR binds to
vitamin D responsive elements VDRE region in the target gene’s promoter [79, 80].
Sequentially, two types of co-activator complexes (SRC then DRIP) bind to VDR
and facilitate the transcription initiation of the target gene [59]. SRC, due to its
histone acyl-transferase activity [81], makes the promoter region more accessible to
other factors [65]. Consecutively, DRIP complex binds and recruits the transcription
machinery components [60, 65]. Cancer tissue significantly over-expresses VDR at
the message and the protein levels, coupled with higher gene expression of both coactivators comparing to other tissue groups.
Our results suggest higher activation of Vitamin D and VDR in BCC tissue
comparing to other tissue groups. According to literature, this may be advantageous
for the patient as it can possibly negatively impact the cancer growth. Vitamin D has
been anticipated to regulate proliferative and differentiating of keratinocytes. This
idea gave rise to the belief that vitamin D supplementation may be beneficial for skin
cancer patients [65, 82, 83].
Some possible mechanism by which vitamin D may exert its anti-proliferative
effect were assessed in tissue samples. The main objective was to investigate
whether our findings are associated with the anticipated impact on BCC tissue. VDR
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is known to negatively regulate mTOR signaling pathway through REDD1. The gene
encoding REDD1 is a VDR target gene [45]. up-regulating this protein promotes the
activation of TSC1/2 complexes, which in turn inhibits Rheb resulting in suppression
of mTOR activity [47]. VDR effect on its target gene was shown to be impaired when
VDREBP are up-regulated as they compete with VDR over the binding sites on the
responsive elements [45]. P-4EBP and p-S6K proteins can be used as indicators of
mTOR activity [48] . Despite the elevated level of VDREBP protein in the cancer
tissue, Protein analysis shows that REDD1 is significantly up-regulated in that tissue
group. However, P-4ebp is also significantly high in that tissue group as compared
to other groups. This interestingly suggests that the expected negative regulation to
mTOR signaling by VDR through REDD1 is compromised in the cancer tissue.
Up-stream of TSC1/2 complex, protein analysis shows that the levels of
phosphorylated AKT, in both S473 and Th308 locations, are significantly elevated in
cancer and proximal tissue comparing to the controls. Active AKT is known to block
the assembly and activation of TSC1/2 complex which opposes with the effect of
VDR.
Ras gain of function mutation result mainly in up-regulating two pathways,
PI3K-AKT-mTOR and Ras-Raf-MEK-ERK pathways [50]. KRas point mutation is
common, and it was implicated with many types of cancers including colon, skin,
and breast cancers [51]. Over expression of KRas gene in all tissue groups of the
BCC patients comparing to the control was concluded from gene expression
analysis. This can possibly result from a gain of function mutation of this gene.
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The presence of a KRas point mutation in BCC tissue specimens was
investigated using ASB-PCR. Among the tested point mutations, only KRas (mut
5.1) Gain of function mutation was successfully detected in our BCC patients
specimens. This mutation was surprisingly detected in all tissue groups from the
cases including the non-cancerous tissue (proximal and distal). In our assay the
(mut 5.1) mutant allele specific primer is anchored at the 3` end with the T base,
which base pairs with the discriminating base in the mutant allele. When the primer
is annealed to the mutated sequence in the cDNA, perfect matching causes the
amplification of the mutant allele. The wild-type specific blocker is a primer that is
complementary of the wild-type allele sequence. Therefore, it perfectly base pairs
with wild-type allele in the cDNA sample. The 3` end of the blocker is
phosphorylated rendering the wild-type allele unamplified.
We suggest that the lost mTOR regulation by VDR is possibly related to the
presence of KRas gain of function mutation. It is possible that the mutation results in
over activation of Ras-PI3K-AKT-mTOR signaling pathway, and hence, overcome
the inhibition effect of vitamin D. However, confirmation of KRas mutation causality
in eliminating vitamin D regulation of mTOR needs further investigation. Upregulation of PI3K-AKT-mTOR pathway was reported in other cancers such as
breast cancer, and it was shown to alter the cancer’s response to endocrine
treatments [48, 49].
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Hedge-hog mutation is characteristic of BCC resulting in excessive signaling
of the pathway [46]. Over expression of Hh-Gli pathway, results in modifying the Gli
code, which affects tumor progression and recurrence [53, 56]. Interestingly, Vitamin
D has the ability to inhibit Hh-Gli pathway and alter the Gli code to promote
differentiation [46, 53]. PTCH was found to block SMO through vitamin D3 and its
derivatives [9, 56]. Studies have shown that providing the active form of vitamin D to
PTCH mutant mouse model reduced Hh-Gli signaling and reduced the incidence of
spontaneous skin cancer in that model [9, 56]. In addition to the direct impact of
calcitriol, VDR seems to have a role in regulating Hh-Gli signaling [9, 46]. Knocking
out VDR resulted in Hh protein ligand over expression, and hence up regulated HhGli signaling [9]. Vitamin D supplementation was projected to be beneficial for
prevention and treatment of skin cancer [84].
Despite the up-regulation of both vitamin D activation gene 1α-OHase and
VDR in cancer tissue specimens, Gli 1 gene is significantly overexpressed in that
tissue group. The expected impact of higher activation of vitamin D and its receptor
on inhibiting Hh-Gli signaling was not observed in our tissue samples. Other
investigators revealed a cross talk between mTOR/S6K1 pathway and Hh-Gli
pathway. Their results suggest that up regulation of mTOR pathway can cause SMO
independent activation of Gli1 [85]. Therefore, we expect that the up regulation of
mTOR pathway that we have observed in BCC samples may contribute to Gli1.
Concomitantly, we propose that the up regulation of mTOR in our BCC samples
opposes the effect of vitamin D on Hh-Gl1 signaling. Both vitamin D and VDR
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impact PTCH capacity to block SMO, while mTOR/S6K1 up-regulates Gli1
downstream of SMO [57, 85].
Up regulation of Hh-Gli pathway was shown to overexpress the anti-apoptotic
gene Bcl2, and Gli2 protein seems to be responsible for that [52]. This is compatible
with our results that show significant over expression of Bcl2 in the cancer tissue.
On the other hand, other publications reported that pathology of basal cell
carcinoma reveals the presence of a large number of apoptotic bodies in BCC tissue
[71, 86]. Also, analysis of mitotic and apoptotic indexes showed that BCC has high
proliferation associated, with high apoptosis which was suggested to contribute to
the benign nature of this tumor [63]. In harmony with that, our data shows that
caspase-3 gene expression is up regulated in BCC cancer tissue comparing to all
other tissue groups, which may predict high apoptotic activity. This finding doesn’t
contradict with our previously observation of elevated Bcl2 expression. Bcl2 can
solely impact the intrinsic apoptosis pathway. Besides, Bcl2 effect on apoptosis is
dependent on BAX/Bcl2 protein ratio [72]. Bax is a pro apoptotic protein from Bcl2
family, which competes with Bcl2. When in excess, Bax counters Bcl2 activity and
releases Cytochrome C from the mitochondria, and thus activates caspase-3 [72].
Active P53 protein up-regulates MDM2 transcription, which in turn, binds and
deactivates P53 as a feedback inhibition mechanism [87, 88]. Recent research
revealed interactions between VDR and p53/MDM2 [68, 89]. VDR promoter region
contains P53 responsive element. MDM2 promoter contains both P53 and VDR
responsive elements. Both responsive elements were shown to cooperate in MDM2
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transcription activation [67, 68]. Also, MDM2 is phosphorylated by S6K1, which
inactivate MDM2 and inhibit its ability to bind P53. This means that the normal down
regulation of mTOR pathway by VDR would result in reduced MDM2
phosphorylation. Consequently, this is expected to yield more MDM2 in the nucleus
to inactivate p53. In our cancer tissue samples, gene analysis revealed that P53
gene is overexpressed. MDM2 gene was also found to be overexpressed in that
tissue group in spite of the elevated levels of VDREBP. However, our earlier results
suggest that the down regulation of mTOR/S6K1 by VDR is diminished in this tissue
group. Thus VDR overexpression in cancer tissue is not expected to reduce MDM2
phosphorylation and inactivation. However, further steps to investigate MDM2
phosphorylation are required to confirm that conclusion.
Recently, the relation between P53 and VDR was shown to be more
complicated than it was thought. P53 is a tumor suppressor gene that may get
inactivated due to a loss of function mutation in many types of cancers[88].
However, it was revealed that some mutant P53 acquire oncogenic activity [10]. P53
gain of function mutations were reported in many types of cancer including skin
cancer [10].
Further interrelationship was found between GOF mutantP53 and vitamin D.
Mutant P53 was found to up-regulate VDR, increase its nuclear localization, and
facilitate its binding to VDRE [89]. In contrast mutant P53 inhibited VDR down
regulation of the genes that have inverse VDRE in their promoter. What is more,
mutant P53 was shown to manipulate VDR transcriptional activity, converting
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vitamin D from a pro-apoptotic to an anti-apoptotic agent. Consequently, it was
concluded that P53 status can manipulate the impact of vitamin D on tumor cells
[89]. Investigating whether the overexpressed P53 in our tissue specimen is a wild
type or mutant protein is an important future direction. In case P53 is mutated in our
BCC specimens, testing for possible impact on VDR activity will be the second
logical step.
Vascular endothelial growth factor (VEGF) is a vitamin D target gene, which
contains VDRE in its promoter [70]. Our gene expression analysis of VEGF
indicated that this gene is over expressed in both cancer and proximal tissue. These
are the same tissue groups that are overexpressing 1αOHase. However, VEGF up
regulation is greater and statistically significant in the proximal tissue, which is
sometimes referred to as “feeding cells”. VEGF protein binds to the VEGFR2
receptor on the plasma membrane of nearby vascular endothelial cells promoting
angiogenesis and providing blood supply to the new tumor growth[90]. VEGF
expression is also up regulated by Ras-MEK-ERK and by PI3-AKT[91]. In our study,
we have shown that both Ras and AKT are up-regulated in the proximal tissue
samples. Besides the over expression of both (1αOHase, and 25OHase) vitamin D
activating enzymes, VDREBP protein that competes with VDR over the response
elements in the target genes promoter is extremely low in this tissue groups. We
suggest that these factors may contribute to the observed up regulation of VEGF in
the proximal tissue group.
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We tested the expression of three genes related to DNA damage repair in our
tissue groups. APEX-1 (apurinic/ apyrimidinic endonuclease 1/redox factor1) is a
key enzyme in Base excision repair; it facilitates the removal of AP sites from the
damaged DNA region [92]. Apex-1 gene expression is lower in the non-cancerous
specimens from patients as compared to the cancer tissue. Both proximal and distal
locations have equal expression of this gene. This may indicate lower BER activity
in the non-cancerous tissue of BCC patients than in the cancer location.
GADD45A is another DNA repair gene that was tested in this study. This
protein regulates nucleotide excision repair, especially when damage is caused by
UV radiation [92] . It interacts with the chromatin and aids in recruiting the
nucleotides and other NER factors [93]. GADD45A expression is the highest in the
cancer tissue and it shows gradual decrease in the normal tissue. All our tissue
specimens are excised from locations that are exposed to UV light, specifically head
and nick, thus UV induced DNA damage is predicted. GADD45 A was shown to be
directly regulated by VDR at the transcription level as well as the post translational
modification level [78]. Also, GADD45A is known to be regulated by P53 [92]. Both
VDR and P53 were shown previously to be over expressed in our cancer tissue
group. GADD45 was also proposed to contribute to the BER pathway. It was
suggested that it facilitates Apex-1 interaction with PCNA [92].
PARP-1 Protein is involved in many important cellular functions; mainly DNA
single-strand and double-strand breaks repair, chromatin remodeling, transcription
regulation, and cell death. Post translational modification can favor one function of
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PARP-1 over the other [73]. We have seen over expression of PARP-1 gene in the
cancer tissue over all other tissue groups from cases and controls. Vitamin D is
known as PARP-1 inhibitor, which contributes to Vitamin D anti-inflammatory
property[94]. Vitamin D mediated PARP-1inhibition can occur at the expression
level[74], or via post translational modification [94]. VDR was also shown to inhibit
PARP-1 cleavage by caspase-3 [34]. Our data is inconclusive in regards to PARP-1
activity due to its regulation by post-translational modifications. However, taking in
consideration the expression of the three genes, we predict higher repair activity in
cancer tissue comparing to other non-cancerous tissue of BCC patients and
controls.
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Figure 4.1: Negative regulation of mTOR by vitamin D is lost in
BCC tissue: results suggest higher activation of Vitamin D and VDR in
BCC tissue. Protein analysis shows that REDD1 is successfully upregulated in cancer tissue despite the elevation in VDREBP. P-4EPB
protein analysis reveals that it the expected negative regulation to mTOR
signaling by VDR is absent in the cancer tissue. Point mutation in Kras
gene was detected in tissue specimens obtained from BCC patients. Our
results suggest that the lost mTOR regulation by VDR is possibly related
to the presence of KRas gain of function mutation which results in over
activation of Ras-PI3K-AKT-mTOR signaling pathway, and hence,
overcome the inhibition effect of vitamin D.
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Figure 4.2: Vitamin D over-activation in BCC tissue is not resulting in
reduction of Hh-Gli pathway signaling: despite the upregulation of vitamin
D avtivation gene 1α-OHase in BCC tissue samples, Gli 1 expression
analysis showed significant up-regulation in the cancer tissue specimens
of BCC patients. The predicted impact of vitamin D in reducing Hh-Gli
signaling and blocking Gli1 expression was not found in our tissue
samples. Others showed that a cross talk between PI3K-AKT-mTOR
pathway and Hh-Gli pathway may be implicated with SMO independent
activation of the later pathway.
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Figure 4.3: VDR role in P53-MDM2 regulation: Active P53 protein upregulates the transcription of MDM2 protein which in turn binds and
deactivates P53 as feedback inhibition mechanism. Recent publications
revealed VDR involvement in this mechanism in their experimental
model. VDR promoter region contains P53 responsive element, and
MDM2 promoter contains both P53 and VDR responsive elements which
were shown to cooperate in MDM2 transcription activation. In our BCC
tissue specimens, we found that BCC cancer tissue that up regulate
VDR also show over expression of MDM2 in spite of the elevated levels
of VDREBP. Also, P53 gene expression was found to be elevated as
well.
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CHAPTER 5: SUMMARY AND FUTURE DIRECTIONS:
The main goal for this study is to interpret the impact of vitamin D
status on the onset and progression and possibly treatment of basal cell
carcinoma. Most of human studies in literature in regards to vitamin D
and NMSC are epidemiological. Mechanistic studies about BCC are few,
and mostly are animal models or cell cultures.
The

unique

approach

for

this

study

involves

human

tissue

samples taken from cancer patients and cancer-free individuals from
southeast Michigan. This study design exclusively distinguishes between
the behavior of non-cancerous tissue from cancer patient and tissue from
cancer-free patients. We are also establishing the alterations in the
genetic

profile

of

patient’s

non-cancerous

tissue

according

to

their

location in relation to the cancer. This idea has a great significance in
understanding factors that may influence the onset and progression of
the disease, as well as the risk for future recurrence.
In conclusion, we believe that the anticipated role of vitamin D is
not conserved in basal cell carcinoma cells. We have observed that
Vitamin

D

ability

to

negatively

regulate

mTOR

and

Hedgehog-Gli

signaling pathways was diminished. In addition, BCC cancer tissue and
its feeding cells seem to

up-regulate vitamin D activation

enzymes,

vitamin D receptor along with its co-activators proposing higher local
activity of vitamin D in the cancer tissue.

134

In our samples, BCC cancer tissue specimens have acquired a
gain of function mutation in KRAS gene, with up-regulation in PI3k-AKTmTOR pathway. Interestingly, Kras mutation was also observed in the
cancer-free

specimens

from

BCC

patients.

We

suggested

that

this

finding possibly contribute to the observed lack of sensitivity of BCC
tissue to Vitamin D effect. However, proving causality needs further
investigation.
This will be the first planned future direction related to this study.
This goal can be approached using cell cultures of BCC cells that carry a
KRAS mutation similar to the one we identified in our tissue samples.
Our goal will be to show that silencing the mutated KRAS may result in
down regulation of mTOR pathway in response to adding vitamin D to
the media.
P53 was also found to be up regulated in our cancer tissue
samples. It unknown whether the expressed P53 in these samples is a
wild type or a mutant form. P53 mutations are common in many types of
cancers including skin cancers. It was suggested in literature that P53
status can manipulate the impact of vitamin D [89]. It was shown that this
impact is related to binding of mutant P53 to VDRE [89].
Investigating P53 and its possible interaction with vitamin D in
BCC is important to understand and interpret our results. Thus, it will be
a future direction for this study. P53 mutation can be possibly detected
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by

allele

specific

primer

and

blocker

Real-time

PCR.

If

P53

is

successfully detected in BCC tissue samples, a mobility shift assay may
determine

binding

of

P53

to

vitamin

D

response

elements

in

our

experimental model. Cell cultures can then be used to inspect whether
silencing the mutant P53 will result in alterations in the cells response to
vitamin D.
Our

data

propose

privation

of

the

benefits

expected

from

supplementing BCC patients with high doses of vitamin D. However, it
does not suggest a detrimental effect of vitamin D for those patients.
Vitamin
[61,

D

62].

possesses
BCC

a

well-characterized

cancer

statistics

immune

shows

an

suppression

association

effect

between

compromised immune function and high incidence of BCC with worse
prognosis,

especially

weakening

medications

regulation of

among
such

VD3 1α-OHase

people
as

who

organ

takes

transplant

was observed

immune
patients

response
[2].

Up

in alveolar macrophages

isolated from lung cancer patients [95]. It was suggested that local
activation of vitamin D around the cancer may be beneficial for the
cancer. It possibly prevents possible immune system attacks to the
cancer cells [95].
Studying the impact of vitamin D supplementation on the immune
response of BCC patients and its possible effect on the disease outcome
makes our second future direction. Achieving this goal can start with
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isolating immune cells from the cancer and proximal tissue. Isolated cells
can be studied for 1α-OHase expression, degree of maturation. Actual
binding of VDR to the inverse response elements in the promoters of the
target genes that which may deteriorate the maturation, may be detected
through mobility shift assay.
Skin cancer is mainly classified as melanoma and non-melanoma
skin cancer. Non-melanoma skin cancer is classified, in turn, to many
subtypes including but not limited to basal cell carcinoma, squamous cell
carcinoma.

Many

health

care

professionals

tend

to

generalize

their

findings regarding skin cancer to include all non-melanoma skin cancer
types.
We tried to investigate whether our conclusions applies to all
NMSC.

Tissue

specimens

Vitamin D metabolism

were

genes

collected

from

were analyzed

in

three

SCC

comparison

patients.
to

BCC

specimens. We concluded that BCC and SCC are acquire different
behavior

in

regards

to

vitamin

D

metabolism,

thus

generalizing

our

conclusions to NMSC would have been a scientific mistake. However,
Full assessment of vitamin D possible effect on other types of skin
cancer such as SCC and MM is another possible future direction for our
research group.
New experiments need to be designed and established for that
purpose.

Subject

recruitment

and

sample

collection

followed

by
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repeating

the

procedures

that

were

used

in

studying

BCC

will

be

repeated with other types of NMSC.
In conclusion, we suggest that supplementation of Vitamin D to
BCC

patients

has

no

expected

benefit.

We

also

propose

that

the

outcome of future steps of this this study will have a greater biologically
significance if we prove a detrimental effect of Vitamin D with respect to
progression of BCC. If we find that cancer progression and the risk of
recurrence is modifiable in individuals by selecting the best regimen for
maintaining adequate levels of vitamin D, the current requirement, and/or
supplementation of vitamin D recommended by health care providers
may become outdated.
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The relationship between Vitamin D and NMSC is not very clear. Most of human
studies in literature in regards to vitamin D and NMSC are epidemiological which are
inconsistent and inconclusive. Mechanistic studies about BCC are few, and mostly are
animal models or cell cultures.
The main goal for this study is to interpret the impact of vitamin D status on the onset
and progression and possibly treatment of basal cell carcinoma. Three tissue samples were
collected from BCC patients (Cancer, Proximal, and Distal), and from cancer-free
individuals from southeast Michigan. This study design helps identifying alterations in the
genetic profile of patient’s non-cancerous tissue based on their location in relation to the
cancer. This idea has a great significance in understanding factors that may influence the
onset and progression of the disease, as well as the risk for future recurrence.
We have observed that Vitamin D ability to negatively regulate mTOR and
Hedgehog-Gli signaling pathways was diminished. In addition, BCC cancer tissue and its
feeding cells seem to up-regulate vitamin D activation enzymes, vitamin D receptor along
with its co-activators proposing higher local activity of vitamin D in the cancer tissue.
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In conclusion, we believe that the anticipated role of vitamin D is not conserved in
basal cell carcinoma cells.
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